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ABSTRACT
Dysregulated inflammation is at the heart of countless human diseases. Graft
rejection is the process by which an organ from an incompatible donor is rejected by the
recipient whose immune cells attack the foreign tissue. Colitis is an inflammatory disorder
caused by undue chronic inflammation in the colon and rectum that can progress to cancer.
Colitis incidence is on the rise, especially in developing nations and Asia; and the list of
patients who need organ transplants grow by the day. Therapies for both graft rejection and
colitis are limited to immunosuppressive drugs that leaves patients vulnerable to infection,
heart disease, nephrotoxicity and malignancy. Thus, new strategies to address the
immunological problems facing these conditions are critical. In this dissertation, we tried
to identify epigenetic, molecular, and cellular pathways involved in inflammation as seen
during allograft rejection or development of colitis.

Data is presented regarding the

expression of a pro-inflammatory microRNA cluster that is up-regulated with graft
rejection, that when silenced, can provoke anti-inflammatory changes to the transplanted
graft, providing a role for epigenetic modulation of inflammation. We also tested the role
of cannabinoid receptors in regulating inflammation through use of natural compounds
such as Δ9-tetrahydrocannabinol (THC), found in Cannabis sativa plant. THC was highly
effective in suppressing colitis through complex pathways involving stimulation of
colonocyte mucin production and barrier integrity mediated by tight-junction proteins to
provide spatial separation between host and commensal organisms. In addition, THC
modulated dendritic cell (DC) phenotype towards increased CD103 expression in the
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colonic lamina propria (cLP) and enhanced DC TGF-β1 expression to expand the cLP
Tregs. The current study has identified novel pathways of inflammation that can be targeted
to benefit patients suffering from inflammatory diseases.
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CHAPTER 1
INTRODUCTION
1.1 ALLOGRAFT REJECTION AND ORGAN TRANSPLANTATION
Organ transplantation is a life-saving, ultimate resort for people undergoing
end-stage organ failure. Thanks to an armamentarium of immunosuppressive drugs, graft
loss due to acute rejection is rare; however, chronic allograft failure persists, and
immunosuppression leaves patients vulnerable to infection, heart disease, nephrotoxicity
and malignancy, among others (1-2). Exciting developments in the generation of ex vivo
expanded T regulatory cells (Tregs) are promising candidates for suppressing graft
rejection sans global immunosuppression (3-6). However, increased attention is needed
into the mechanisms that dictate and control the generation of antigen-specific Tregs, to
prevent them from reverting to a pro-inflammatory phenotype once they are introduced
into the diverse cytokine milieu found in vivo. As shown by others, there exists
opportunities for Treg differentiation into Th1 and Th17 lymphocytes during inflammation
(7-8). In an inflammatory environment, Tregs may undergo reprogramming, wherein the
Treg-specific demethylation region (TSDR), which is constitutively demethylated in
Tregs, may become methylated, or partially methylated with peripheral Tregs (pTregs),
leading to a loss in Foxp3 expression and immunosuppressive activity, conferring an
acquired proclivity for graft destruction in the reprogrammed cells (9-10). Investigations
in recent years have delved into the factors dictating the differentiation (12-13), generation
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(11, 13), and functions (11, 20-22) of Treg cells. Nevertheless, there remains a need for
increased attention into the factors that can confer stable Treg suppressive activity.
1.2 MICRORNA
MicroRNAs (miRNAs) are one of the critical players of T cell function and
plasticity (16-19). miRNAs are a group of, short, single stranded, ~21 nucleotide-long
RNA sequences that bind to the 3’ untranslated region (UTR) of target mRNAs through a
6-8 nucleotide ‘seed sequence’, generally leading to degradation of target mRNA or
inhibition of translation (18). MiRNAs are heavily influential in several areas of Treg
biology, such as the effect of miR-155 on Treg fitness (21), miR-146a on Treg control of
T helper suppression, specifically Th1 responses (22-23) and miR-21’s role in Treg
expansion (24-25). However, there remains a paucity of information concerning what
miRNAs hinder Treg generation in inflammatory models. One factor critical to the
development of FoxP3+ regulatory T cells is Transforming Growth Factor-Beta1 (TGFβ1). At first contentious, many studies have since highlighted an indispensable role for
TGF-β1 in the differentiation and generation of Tregs. Both thymic intra-medullary naïve
CD4 cells (CD4+CD8-CD25-), and peripheral naïve CD4 cells can be differentiated into
FoxP3 expressing Tregs after TCR stimulation in the presence of TGF-β1 (14,15).
1.3 TGF-β AND T REGULATORY CELLS
TGF-β1 is a pleiotropic cytokine from the TGF-β signaling pathway superfamily
that plays a role in virtually all cell processes starting from development to differentiation
and apoptosis (65-68). In the context of immunity, much is known about the antiinflammatory properties of TGF-β1. It acts through reducing effector cell generation and
proliferation as well as by inducing anti-inflammatory Tregs (11,65). Tregs are a CD4+ T
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cell subset that express the transcription factor FoxP3 and quench inflammation by
inhibiting inflammatory effector cells through a variety of mechanisms including: direct
cell-cell contact, increased IL-2 uptake, adenosine release, and TGF-β1 secretion and
activation, among others (10-15). Although the types of Tregs are still increasing, they fall
into two main subsets, natural and peripheral Tregs, nTregs and pTregs, respectively.
Natural or thymic Tregs arise in the thymus and protect the body against auto-immunity
after complex interactions with specialized thymic antigen presenting cells (APCs) lead to
Tregs with high avidity for self-antigens. Peripheral or induced Tregs, as the name
suggests, arise in the periphery through a TGF-β1 dependent mechanism and allows for the
tolerance to environmental antigens that are beneficial to the host (10-15,58,60). While the
role for TGF-β1 in immunity is established and expanding; another TGF-β superfamily
member, TGF-β2, has received a fraction of the interrogation into its immunomodulatory
capacity. TGF-β2 is mainly studied in the context of development and Loeys-Dietz
syndrome (69,70). Although some studies show anti-inflammatory properties available to
TGF-β2 (78,79), and its expression in immune-privileged tissues like the eyes and testes
implicate a role for immunity, more work needs to be done to examine its role in Treg
induction and the resolution of inflammation.
1.4 COLITIS AND COLITIS-ASSOCIATED COLON CANCER
The mammalian gastro-intestinal (GI) tract provides the architecture for solid and
liquid nutrient absorption, while harboring a diverse and vast array of microbes to
maximize catabolic potential for the host. The interplay between absorptive epithelial cells,
surveilling immune cells and commensals calibrate according to age, diet, genetics,
geography, immunity, xenobiotics and numerous other environmental and behavioral
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variables (26). A perturbation in any of these factors in the GI tract can cause inflammatory
bowel diseases (IBD), encompassing Crohn’s disease (CD) and ulcerative colitis (UC).
These chronic idiopathic conditions are a major health concern, with prevalence in North
America and Europe reaching 3.5 million people (27). Although immunomodulatory
corticosteroids, anti-TNFα antibodies and 5-ASA therapies have shown potent remissioninducing ability for IBD patients, they are accompanied by risks for infusion reactions and
immunosuppression leading to opportunistic infection and malignancy (28). It has been
shown conclusively that, besides the pernicious effects of IBD, those afflicted have an
increased risk of developing colorectal cancer (CRC) during their lifetime (29,30).
The precise pathological mechanisms underlying the development and progression
of IBD remain unclear, however certain factors predispose or stave off developing disease.
Host genetics can predispose an individual to IBD (31,32), and uncontrolled inflammation
via mutation or dysregulated immunogenicity to commensals or dietary antigens precludes
the causative pathology in IBD (33). Exogenous factors such as diet and microbial
community have been recognized as significant contributors to the pathogenesis and
prevention of IBD, such that a ‘western’ diet will predispose an individual to IBD, while a
diet high in fiber promotes the production of mucus to protect gut epithelial lining and
provide a matrix and substrate for which beneficial bacteria can flourish (34-36). Although
many studies have investigated the specific microbial clades influencing IBD, no
consensus has been reached, and the emerging hypothesis is that perturbations to the
collective GI microbiome, deemed dysbiosis, contribute to IBD progression (37). The
advances in biologics targeting inflammation, and beneficial effects of diet and exercise on
IBD have stemmed the incidence of IBD in the westernized world; however, recent
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epidemiological data suggest an accelerating incidence of disease in newly industrialized
nations and Asia, highlighting a need for therapies and strategies that address multi-faceted
mechanisms of disease prevention (27,28,38).
1.5 CANNABINOIDS
Cannabinoids are a class of chemically unique compounds that bind to
evolutionarily conserved yet geographically and functionally distinct G protein-coupled
receptors: cannabinoid receptors 1 (CB1) and 2 (CB2). The first two exogenous ligands for
the cannabinoid receptors to be discovered were Δ9-tetrahydrocannabinol (THC) and
cannabidiol (CBD), the two main natural products derived from the plant Cannabis sativa.
Investigation into CB1 and CB2 led to the discovery of the endogenous cannabinoids, Narachidonoyl-ethanolamine (AEA) and 2-arachidonoylglycerol (2-AG), which are
synthesized on demand as bioactive lipids from the precursor arachidonic acid (39-41).
Many early studies investigated the psychoactive properties of THC, but recent work, along
with a plethora of largely anecdotal reports (41,42), have hailed THC, its non-psychoactive
cousin CBD, and the endocannabinoids for their therapeutic potential in conditions of
autoimmunity, spasticity, nausea and pain management (42,43). Cannabinoid receptor
activation leads to a robust anti-inflammatory response, largely characterized by reduced
antigen-presenting cell (APC) activation (44), a switch from a T helper 1 (Th1) phenotype
to a T helper 2 (Th2) phenotype, and a direct induction of apoptosis in activated T cells
(46-48). In the GI tract, cannabinoids exert a host of anti-colitic effects, demonstrated in
several models (48-50). Activation of CB2 in the gut prompts anti-inflammatory responses
that can ameliorate the symptoms of colitis, while activation of CB1 leads to reduced GI
motility, gastric emptying, and increased epithelial integrity (48-52). Further support for
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the notion that cannabinoids have therapeutic potential for IBD is that knockout mice
lacking CB1 or CB2 develop more severe colitis symptoms (52,53). Despite the plethora
of data from pre-clinical studies on the effectiveness of cannabinoids for IBD, only two
clinical studies have been conducted, and there remains a lack of understanding how the
myriad functions of cannabinoids work collectively to influence colitis development and
progression (53-56).
1.6 PROBLEM AND HYPOTHESIS
The process of allograft rejection and colitis are instances of allo- and
autoimmunity, respectively, that encompass inflammation and thus treatment modalities
that target inflammation are desired. The burden of these conditions on patient quality of
life, risk of cancer development, and increasing health care costs are staggering (1-3,2628). There is an acute need to find remedies that re-program our immune system towards
graft acceptance in the case of graft rejection, and to find preventative therapeutic options
in the case of colitis. Therefore, we examined how to fine-tune the immune system in the
case of graft rejection so that a natural epigenetic change that occurs in the host to dampen
anti-inflammatory processes is suppressed, allowing increased Treg induction to stave off
graft rejection. We explored the mechanism through which cannabinoids beneficially
impact the complex interplay between colonic epithelial cells, underlying immune cells
and the commensal microbiota to provide protection from colitis using mouse and human
cell lines using CB antagonists, several animal models of colitis, and a model of colitisassociated CRC.
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CHAPTER 2
MIR-466A TARGETING OF TGF-Β2 CONTRIBUTES TO FOXP3+ REGULATORY T
CELL DIFFERENTIATION IN A MURINE MODEL OF ALLOGENEIC
TRANSPLANTATION1

2.1 ABSTRACT
The promise of inducing immunological tolerance through Regulatory T cell (Treg)
control of effector T cell function is crucial for developing future therapeutic strategies to
treat allograft rejection as well as inflammatory autoimmune diseases. In the current study,
we used murine allograft rejection as a model to identify microRNA (miRNA) regulation
of Treg differentiation from naïve CD4 cells. We performed miRNA expression array in
CD4+ T cells in the draining lymph node (dLN) of mice which received syngeneic or
allogeneic grafts to determine the molecular mechanisms that hinder the expansion of
Tregs. We identified an increase in miRNA cluster 297-669 (C2MC) after allogeneic
transplantation, in CD4+ T cells, such that 10 of the 27 up-regulated miRNAs were all from
this cluster, with one of its members, mmu-miR-466a-3p (miR-466a-3p), targeting TGFβ2, as identified through reporter luciferase assay. Transfection of miR-466a-3p in CD4+
T cells led to decreased inducible FoxP3+ Treg generation while inhibiting miR-466a-3p

1

Becker W, Nagarkatti M, Nagarkatti PS. miR-466a Targeting of TGF-β2 Contributes to
FoxP3+ Regulatory T Cell Differentiation in a Murine Model of Allogeneic
Transplantation. Front Immunol. 2018;9:688.
Reprinted here with permission of publisher.
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expression through Locked Nucleic Acid (LNA) resulted in increased Tregs, and a
reduction in effector T cells. Furthermore, in vivo inhibition of miR-466a-3p in an
allogeneic skin graft model attenuated T cell response against the graft through an increase
in TGF-β2. TGF-β2 was as effective as TGF-β1 at both inducing Tregs, and, through
adoptive transfer, mitigating host effector T cell response against the allograft.
Collectively, these data demonstrate for the first time a new role for microRNA-466a-3p
and TGF-β2 in the regulation of Treg differentiation and thus offers novel avenues to
control inflammatory disorders.
2.2 INTRODUCTION
Allograft rejection is a robust T cell-mediated immune response involving
activation of a large proportion of T cells that are alloreactive. We used that as model to
study how Tregs are silenced. To that end, we performed expression profiling of miRNAs
in CD4+ T cells found in the draining lymph node (dLN) of mice that received tail skin
allografts to identify miRNA that influence the generation of Tregs.

Our results

demonstrate that a cluster of miRNA is upregulated after alloantigen exposure, specifically
in dLN CD4+ T cells, that act to suppress TGF-β2, resulting in decreased Treg generation
and increased inflammation. The accumulated data suggests a unique role for TGF-β2 in
the regulation of Tregs and therefore opens new avenues to treat not only allograft rejection
but other inflammatory disorders.
2.3 MATERIALS AND METHODS
Animals The University of South Carolina Institutional Animal Care and Use
Committee approved all experiments. All mice were housed at the AAALAC-accredited
animal facility at the University of South Carolina, School of Medicine (Columbia, SC),
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and given ad libitum access to water and normal chow diet. Female C57BL/6 (H-2b wildtype, BL6) and C3H (H-2k, C3H) mice, aged 8-12 weeks, with an average weight of 20g,
were obtained from Jackson Laboratories (Bar Harbor, ME, USA). C57BL/6-FoxP3GFP
mice were bred and maintained in-house. The number of mice for each experimental cohort
is described in the figure legends. Each experiment was repeated at least twice, and in many
cases, three or four times.
Skin Transplant, LNA-based Treatment, and Adoptive iTreg Transfer
Transplantation of tail skin from donor (C3H, allograft; C57BL/6, syngeneic graft) to
recipient C57BL/6 mice, was carried out as described previously (83). Skin grafts were
obtained by excising the tail from donor mice, and splitting the tail into equivalently sized
~1x1 cm2 grafts. Recipient mice were anesthetized by an intraperitoneal injection of
ketamine (80mg/kg) and xylazine (12mg/kg) (Southern Anesthesia & Surgical, Columbia,
SC) in molecular grade water. Upon sufficient anesthetic depth, mice were shaved and
~1x1 cm2 graft beds were made using curved scissors on the dorsal lateral surface. Donor
skin grafts were placed onto the graft beds and mice were bandaged. Mice were monitored
and kept in bandages for 7-9 days following skin transplantation surgery. In studies using
Locked Nucleic Acid (LNA)-based miRNA inhibitor (anti-miR-466a-3p, Exiqon), the
LNA (10mg/kg) was injected i.p. to graft recipient mice 1 day before skin transplant, and
then every 3rd day after that until termination of the study. For studies involving expanded
iTregs, these cells were cultured as described below, sorted for CD4+, FoxP3-GFP
expression using BD FACSAria II, and 1x106 iTregs were adoptively transferred 1 day
before skin-grafting. For graft rejection scoring, mice were scored as +/+, viable graft; +/, partially rejected the graft (>50% scabbed over or necrotic, or >50% reduction in graft
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size); or -/-, fully rejected the graft (>80% necrotic). For depicting graft survival, +/+ and
+/- skin grafts were considered viable, and -/- skin grafts were considered nonviable. The
log-rank method was used to determine differences in graft survival.
Target Prediction and Luciferase Reporter Assays Relevant targets for miR-466a3p and other miRNAs were investigated by cross-referencing predictions from TargetScan
Mouse 6.2 software using a context+ score threshold greater than -0.02 and microRNA.org
using a mirSVR score between -1.2 and -0.2. The 3’ UTR of candidate gene targets or
mutated control were purchased from Integrated DNA Technologies (IDT) and cloned
immediately downstream of luciferase in the pMiReport vector (Promega, Madison, WI,
USA). Insertion of candidate mRNAs was verified through PCR and agarose gel
electrophoresis. For luciferase assays, 2.5 x 105 EL-4 cells were plated in 24-well plates
for 24 hr and subsequently transfected with either luciferase reporter constructs, together
with miR-466a-3p mimics or the negative scramble control (Qiagen, Valencia, CA) using
lipofectamine 3000 (Life Technologies). At 48hr post-transfection, dual luciferase assay
system (Promega, Madison, WI, USA) was used to detect luciferase activity. Normalized
data were calculated as the quotient of Renilla/firefly luciferase activities. The experiments
were performed in duplicate and repeated at least 3 times.
Cell Culture Cells were cultured in a sterile incubator that was maintained at 37°C
and 5% CO2. EL-4 cells were cultured in DMEM supplemented with 10% fetal bovine
serum, 100 U/mL penicillin and 100 U/mL streptomycin. Primary cells were cultured in
complete RPMI supplemented with 10% FBS, 100 U/mL penicillin, 100 U/mL
streptomycin (both Gibco), 10mM HEPES (Gibco, Paisley, UK), and 50 μM βmercaptoethanol (Sigma-Aldrich, Gillingham, UK) (complete medium).
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Treg Polarization, CD3/CD28 Stimulation and miRNA Transfection For Treg
polarization and CD3/CD28 stimulation studies, naïve lymph nodes were harvested and
processed into single-cell suspensions. CD4+ T cells were purified using EasySep PE
Positive Selection Kit (Stemcell Technologies, 18557). CD4+ T cell purity was routinely
>90% as verified through flow cytometry. Cells (1x 106) were plated in 12 well plates in
complete medium supplemented with plate-bound anti-mouse CD3ε, clone 145-2C11
(3µg/mL) in the presence of anti-mouse CD28, clone 37.51 (3µg/mL). For studies
examining only CD23/CD28 stimulation, cells were harvested 48hr after plating for
downstream analysis. For Treg polarization, cells were plated with recombinant mouse IL2 (5ng/mL) and recombinant human TGF-β1 (5ng/mL) or recombinant TGF-β2 (5ng/mL)
(R&D Systems, Minneapolis, MN) where indicated, in addition to the aforementioned
amounts of CD3 and CD28. Five days after plating, cells were harvested for downstream
analysis and cell culture supernatants were collected for ELISAs. All cytokines were
purchased from Biolegend (San Diego, CA). In both experiments, cells were transfected
with either 25 nM miR-466a-3p mimic (UAUACAUACACGCACACAUAAGA), 100nM
miR-466a-3p inhibitor (UAUACAUACACGCACACAUAAGA), or 25 nM scramble
control, using HiPerfect Transfection Reagent from Qiagen (Valencia, CA). Transfection
efficiency was validated using qRT-PCR.
iTreg Generation CD4+ T cells from BL6 FoxP3GFP mice were purified using
EasySep PE Positive Selection Kit (Stemcell Technologies, 18557). CD11c+ allogenic
APCs were isolated from the spleens of C3H mice using EasySep PE Positive Selection
Kit. The cells were co-cultured for 3 days at a ratio of 5:1, T cells : APCs. Additionally,
anti-CD3ε (10µg/mL), anti-CD28 (4µg/mL) and IL-2 (5ng/mL) were added to all wells
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and TGF-β1 (5ng/mL) and TGF-β2 (5ng/mL) were added where indicated. Cells were cocultured for 72 hours before being collected for downstream analysis or sorted for purity
and injected intravenously.
Alloantigen Co-culture Naïve lymph node cells were harvested and processed
through a 100µm cell strainer to make single-cell suspensions. Cells (1x106) were plated
in the presence of 50 μg/mL of alloantigen or no antigen (control) in complete RPMI in
12-well plates for 10 days. Fresh medium was added on day 5, and LNA-based miRNA
inhibitor (anti-miR-466a-3p, Exiqon, Denmark) and control LNA were added every 3 days
at 50 ng/mL. After 10 days, cells were collected for downstream analysis and cell culture
supernatants were stored at -20°C before being analyzed by cytokine-specific ELISA for:
IFNγ, TNFα, IL-17A, total TGF-β1 (Biolegend, San Diego, Ca), and TGF-β2 (R&D
Systems, Minneapolis, MN).
Antigen Preparation (splenocyte lysates) C3H and C57BL/6 mice were euthanized
and their spleens were aseptically removed, homogenized, and passed through a 100µm
cell strainer to make single-cell suspensions in cold, serum-free media. Red blood cells
(RBCs) were lysed and the cell suspension was washed twice with cold serum-free media.
Then, cells were re-suspended at a cellular density of 1x108 cells/mL and subjected to 4
freeze (5 min liquid nitrogen) – thaw (10 min 37 °C water bath) cycles. Cells were then
sonicated for 5 min, and the lysate was centrifuged at 350g (10 min, 4 °C) and supernatant
was recovered. The lysate was filtered with a 0.22 μm microporous membrane, protein
concentration was determined using Qubit fluorometer (Thermo Fisher Scientific), and
subsequently stored at 4 °C.
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Graft Infiltrating Cell Extraction Mice that received a skin-transplant were
sacrificed and the transplanted graft was aseptically excised. Grafts were cut longitudinally,
minced and digested for 2 hours at 37°C 5% CO2 in PBS containing Type I Collagenase
(2.5 mg/mL) and Hyaluronidase (0.25mg/ml) (both from Sigma). Subsequently, graft
infiltrating cells (GICs) were obtained by spinning at 1000g for 7min at 4°C before being
re-suspended in FACS buffer and live cells enumerated using a hematocytometer, and
either stained immediately for flow cytometry or plated overnight to recover GIC culture
supernatants. Cell-free culture supernatants were recovered and stored at -20°C before
being analyzed by cytokine-specific ELISA.
Flow Cytometry and Antibodies Relevant tissues were harvested and cells were
homogenized and subsequently depleted of red blood cells as described above. To analyze
immunophenotype surface markers, we stained single cell suspensions using the
recommended dilutions indicated on the manufacturer product sheets, and gated them on
PE conjugated anti-CD4 (GK1.5) or FITC conjugated anti-CD8α (53-6.7) where indicated.
Antibodies used for flow cytometric analysis (BioLegend, San Diego, CA, USA) include
Fc block, PE, PE/Cy7 and APC-Cy7 conjugated anti-CD4 (GK1.5), PE and BV421
conjugated CD304 (Neuropilin-1) (3E12), PE conjugated anti-IL-17A (TC11-18H10.1)
Alexa Fluor 488 and BV421 conjugated FoxP3 (MF-14), FITC conjugated Helios (22F6),
APC conjugated IFNγ (XMG1.2), APC and PerCP-Cy5.5 conjugated LAP (TGF-β1)
(TW7-16B4), FITC conjugated CD8α (53-6.7), BV650 conjugated CD223 (LAG-3)
(C9B7W), Alexa Fluor 700 conjugated CD49b. PE conjugated IL-10 (JES5-16E3), PE
conjugated GATA3 (16E10A23), FITC conjugated T-bet (4B10), APC conjugated CD62L
(MEL-14), BV650 conjugated CD278 (ICOS)(DX29), (PE conjugated CD44 (IM7) and
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PE/Cy7 and BV786 conjugated CD25 (3C7). Antibodies against nuclear proteins were
probed using True-Nuclear Transcription Factor Buffer Set (BioLegend, San Diego, CA,
USA) and intracellular cytokine staining was performed using Fixation/Permeabilization
Solution Kit (BD, San Jose, CA). The stained cells were then assessed by flow cytometer
(FC500; Beckman Coulter, Brea, CA, USA) or BD FACSCelesta (BD, San Jose, CA, USA)
and the resulting data analyzed by Cytomics CXP software (Beckman Coulter), DIVA
software, or FlowJo. Sorting of cells was performed using a BD FACSAria II (BD, San
Jose, CA, USA). The gates were set following exclusion of debris. Additionally, we used
positive and negative controls for the fluorophores used. The events were displayed as a
dot plots or as a contour maps to show the relative intensity of scatter patterns. The gates
were set at around populations of cells with common characteristics such as forward
scatter, side scatter and density of marker expression.
miRNA Expression Profiling dLN CD4+ T cells purified to >90% purity using
EasySep PE Positive Selection Kit (Stemcell Technologies, 18557) were subject to total
RNA isolation using miRNeasy kit (Qiagen, Valencia, CA), following manufacturer’s
protocol. The concentration and purity of the isolated RNA were determined using a
spectrophotometer, and the integrity of the RNA was verified using Agilent Eukaryote
Total RNA Nano Series II on an Agilent 2100 BioAnalyzer (Agilent Tech, Palo Alto, CA).
Only samples with a RIN value above 8 were used for subsequent processing. Profiling of
miRNA expression from samples was performed using the Affymetrix GeneChip miRNA
4.0 array platform (Affymetrix, Santa Clara, CA) at the Johns Hopkins Deep Sequencing
and Microarray Core (http://www.microarray.jhmi.edu/) following the manufacturer’s
protocol. This array version covers all mature miRNA sequences in miRBase Release 20
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(http://www.mirbase.org/). The stained chip was scanned on a GeneChip Scanner
(Affymetrix) and microarray image data were analyzed using Affymetrix Power Tools
(APT) to generate Robust MultiArray Average (RMA) values as well as detection above
background (DABG) p-values as well as for normalization and quality control of data.
Hybridization signals that that showed aberrant properties and were <3 standard deviations
over the mean background value were excluded. Statistical significance (p values) for
“detection calls” were determined by Affymetrix test. Probe sets with a p value lower than
0.05 were called present (true). The log-transformed fluorescence intensity values were
mean-centered and visualized by heat maps. miRNA fold changes were obtained from the
array and miRNAs with only a greater than 1.5-fold change were considered for further
analysis. Predicted miRNA targets, alignments, and mirSVR scores were determined using
online miRNA databases:microrna.org, and TargetScan Mouse 6.2. Heatmap was made
using Genesis software (Graz University of Technology). Ingenuity Pathway Analysis
(IPA) (Qiagen, Valencia, CA) was used to identify the molecular and functional
annotations and canonical biological pathways potentially influenced by target genes of
differentially expressed miRNA. The array data were deposited into the Genome
Expression Omnibus (GEO) of NCBI (https://www.ncbi.nlm.nih.gov/geo/) and can be
accessed via accession number GSE109160.
Immunoblotting Cell extracts were collected using RIPA lysis buffer
supplemented with sodium orthovanadate, PMSF and protease inhibitor (Sigma). Protein
concentration was measured using Qubit fluorometer (Thermo Fisher Scientific) and were
subjected to gel-electrophoresis and transfer onto a nitrocellulose membrane. Blots were
blocked with 5% BSA in TBST, washed, and probed overnight at 4 °C with antibodies
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against TGFβ2 (1:1000, R&D Systems, MAB73461), TGFβR3 (1:2000, R&D Systems,
AF5034), Smad2/3 (1:1000, CST, 5678), Phospho-Smad2 (Ser465/467)/Phospho-Smad3
(Ser423/425), (1:1000, CST, 8828), Smad4 (1:1000, CST, 38454) and Phospho-Smad4
(Thr276), (1:1000, Thermo Fisher Scientific, PA5-64712). The next day, blots were
washed in TBST and then incubated at room temperature for 1 h with a horseradish
peroxidase labeled secondary antibody. Following secondary antibody incubations, blots
were washed multiple times with TBST, exposed to a chemiluminescent reaction, Pierce™
ECL Western Blotting Substrate (Thermo Fisher Scientific, Rockford, IL), and were
exposed to film. Optical densities of films were quantified (sample minus background)
using ImageJ.
Measurement of cytokines Cell culture supernatants from indicated in vitro
experiments, graft infiltrating cell culture supernatants obtained ex vivo, or serum samples
were analyzed for the following cytokines: IFNγ, TNFα, IL-17A, total TGF-β1, latent
TGF-β1, and free-active TGF-β1, enzyme-linked immunosorbent assay (ELISA) kits were
purchased from Biolegend (San Diego, CA). For detection of TGF-β2, ELISA kit was
purchased from R&D Systems (Minneapolis, MN).
RNA Extraction and qPCR CD4+ T cells in the dLN or spleens of grafted mice
were purified using EasySep PE Positive Selection Kit (Stemcell Technologies, 18557),
and total RNA was isolated using miRNeasy kit (Qiagen, Valencia, CA), following
manufacturer’s protocol. Expression of indicated mRNA and miRNA levels were
determined by quantitative real-time PCR (qRT-PCR). Quality and amount of RNA was
investigated using Nanodrop 2000 (Thermo Fisher Scientific, Rockford, IL). For miRNA
expression analysis, cDNA was made from total RNA using miRNA cDNA Synthesis Kit,
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with Poly(A) Polymerase Tailing (ABM, Canada, G902). Two-step with hot-start miRNA
qRT-PCR was carried out using EvaGreen miRNA Mastermix (ABM, Canada,
MasterMix-mS) with mouse primers for SNORD96A (control), miR-466a-3p, miR-466e3p, miR-466p-3p, miR-15a-5p, miR-181c-5p, miR-27a-3p and miR-19b-3p (ABM,
Canada). Expression levels were normalized to SNORD96A. For mRNA expression
analysis, cDNA was made from total RNA using miScript cDNA synthesis kit from BioRad (Hercules, CA). Two-step amplification with a 60° annealing temp. for qRT-PCR was
carried out using SsoAdvanced™ SYBR® green supermix from Bio-Rad (Hercules, CA)
with mouse primers for TGFβ1, TGFβ2, TGFβR3, PTEN, FoxP3, Smad2, Smad3,
TGFβR1 and TGFβ3. All qRT-PCR experiments were carried out on a CFX96 (or 384)
Touch Real-Time PCR Detection System (Bio-Rad, Hercules, CA). Expression levels were
normalized to β-actin mRNA levels. Fold changes were calculated using the 2−ΔΔCT
method. Primers are detailed in Table 2.3.
H&E Staining Grafts were excised and fixed by immersion in 4%
paraformaldehyde (PFA) in PBS, overnight. Fixed tissues were embedded in paraffin,
sectioned and stained with hematoxylin and eosin. Color bright field images and picture
montages were taken using a Cytation-5 Imaging Reader (BioTek Instruments, Winooski,
VT, USA).
Statistical Analysis Prism 6 and 7 software (Graphpad) were used for statistical
analysis. In skin graft experiments, we used groups of at least 7 mice. Data were depicted
as means ±SEM. Student’s t test was used to compare data between 2 groups. One-way
ANOVA with a Tukey post hoc test was used to compare 3 or more groups. A log-rank
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(Mantel-Cox) test was used to determine the significance of survival curves. A p<0.05 was
considered significant.
2.4 RESULTS
Draining lymph node T regulatory cell response to allograft
T regulatory cells (Treg) play a critical role in tolerance and the decrease in their
functions is associated with strong inflammation (3-8). To investigate the potential
mechanisms that dampen the basal Treg induction during an immune response, we used an
allogeneic skin-graft model of transplantation. To that end, C57BL/6 mice (H-2b, BL6),
were given age and sex- matched syngeneic (syn) (BL6) or allogenic (allo) C3H (H-2k,
C3H) full thickness ~1x1 cm2 tail skin transplants on the dorsal lateral surface. Ten days
after transplantation, mice were sacrificed and their draining lymph nodes (dLN) and
spleens were harvested and assessed for the type and frequency of Tregs present. Among
the main Treg subtypes, we investigated natural Tregs (nTregs), that are demarcated by
surface CD4+ and Neuropilin-1 (Nrp1) expression, and express the transcription factor
FoxP3 (57,58,60), peripheral Tregs (pTregs) that are CD4+, FoxP3+, Nrp1-, or Nrp1LO
(59,60); and Tr1 T cells, which are CD4+, FoxP3 -, CD25-, CD49b+, Lag-3+ (CD223+),
and express inducible T-cell costimulatory (ICOS). In addition, these cells express higher
latent-associated TGF-β and secrete IL-10 (57,84). In the dLN of allografted mice, but not
in the spleen, there was a significant reduction in the percentage of nTregs and pTregs
when compared to syngrafted mice (Figure 2.1A-E). In contrast, there were no significant
changes in the percentages of Tr1 cells (Figure 2.1F-H). Additionally, when looking at the
amount of latent-associated peptide –TGF-β1 (LAP) on CD4+FoxP3+ cells, we observed
a notable decrease in the percentages of these Tregs in the allograft dLN (Figure 2.1I). Due
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to the requirement of TGF-β1 for pTreg induction, and the decrease in LAP on Tregs after
allotransplantation, we looked at TGF-β1 levels in the serum on the day the mice were
euthanized and found that its presence was diminished after allotransplantation as well
(Figure 2.1J).
A miRNA cluster is altered in dLN CD4+ cells
We next investigated if changes in Tregs were associated with alterations in
miRNA expression because miRNA are known to regulate T cell differentiation and
plasticity. To that end, we isolated total RNA from purified CD4+ T cells in the dLNs of
syn- or allografted mice or naïve mice, pooled the RNA from mice in the same group, and
performed a miRNA expression microarray as a preliminary screening tool using an n of 1
per group. Differential fold change expression of 3,164 miRNAs between the naïve, syn
and allo groups was performed. A table was constructed of all the miRNA from the array
that displayed a 1.5 or greater fold change in the allo group compared the syn group, while
also displaying changes between the allo and naïve group, most of which also displayed a
fold change greater than 1.5, with miR-7648-3p being the sole exception (Table 2.1). A
compelling finding was that 10 of the 27 miRNAs that were found to be up-regulated in
the allo group (compared to both naïve and syn groups) all came from the same cluster of
miRNA that was contained in the 10th intron of the Polycomb group gene Sex combs on
the midleg with four MBT domains-2 (Sfmbt2) on mouse chromosome 2, henceforth
referred to as Chromosome 2 miRNA cluster (C2MC) (Table 2.1). C2MC has also been
referred to as the miR-297-669 cluster (61-63).
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Validation of miR-466a expression and predicted mRNA targeting
Next, we validated the expression of these miRNA through qRT-PCR (Figure
2.2A). Using TargetScan Mouse 6.2 and microrna.org, several of the miRNA that were upregulated after allografting were found to target many members in the family of TGF-β
signaling, consistent with a clear role for TGF-β1 in the differentiation of naïve CD4+ T
cells into pTregs, and tolerance (64-66). These miRNAs and their associated fold changes
were input into Ingenuity Pathway Analysis (IPA) to display them alongside their predicted
targets (Figure 2.2B). Our data indicating a decrease in pTregs, LAP+ Tregs, and
circulating TGF-β1 (Figures 2.1A, D, I, J) suggested that the TGF-β1 pathway may be
attenuated after allotransplantation, an avenue that was further pursued. Among the upregulated miRs, the specific miRNA from C2MC with the highest validated mean
expression in CD4+ T cells draining from the allograft was miR-466a-3p (Figure 2.2A),
henceforth referred to as miR-466a. This miRNA was chosen as the main miRNA of
interest, both because of its noteworthy upregulation (Figure 2.2A), and because the seed
sequence of miR-466a is identical to miR-297(a/b/c)-3p, miR-446d-3p, miR-467g and
miR-669d-3p,

other

members

of

C2MC.

Upregulation

of

miR-466a

after

allotransplantation was specific to dLN CD4+ cells, as it was not significantly altered in
splenic CD4+ cells or other peripheral LN CD4+ cells (Figure 2.2C). Predicted targets of
C2MC in (Figure 2.2B) were validated through qRT-PCR (Figure 2D) to be downregulated in allograft dLN CD4+ cells. We next investigated the mRNA specifically
targeted by miR-466a. Predicted target, binding, and miRSVR score of miR-466a - mRNA
interactions are displayed in a Table (Table 2.2). We cloned the 3’-untranslated region (3’
UTR) of several mRNA of interest (Smad2, Smad3, TGF-β2 and TGF-βR3) as well as a
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mutated 3’ UTR, immediately downstream of luciferase in a luciferase reporter assay. EL4 cells were transfected with the luciferase reporters or a control vector lacking any 3’ UTR
inserts in the presence of either a miR-466a mimic or a scramble control. We found that in
the presence of miR-466a mimic, the luciferase activity of the reporter with the TGF-β2 3’
UTR cloned into its sequence was significantly lower, while such a decrease was not seen
in the presence of the scramble control, any of the other cloned 3’ UTRs, or in the mutated
control group (Figure 2.2E). This finding was consistent with the predicted 7mer-m8 seed
match shared between miR-466a and TGF-β2.
miR-466a targets Treg polarization through TGF-β2
To directly test the role of miR-466a on Treg differentiation, we used an in vitro
Treg polarization model. To that end, purified naïve CD4+ T cells cultured with cytokines
were transfected with either mock (empty vector), scramble control (25nM), mimic
(25nM), or mimic + inhibitor (100nM). The data showed that transfection with mimic, but
not any of the other conditions, could suppress the generation of Tregs as demarcated by
the co-expression of CD4 and FoxP3 (Figure 2.3A-C). It was worth noting that the mimic
caused a robust decrease in the total number of Tregs generated in culture when compared
to controls (Figure 2.3C). Transfection efficiency was validated with qRT-PCR (Figure
2.4A). We next quantified the mRNA and protein levels of the predicted targets of miR466a after transfection and found that the mRNA expression of Smad2, Smad3, TGF-β1,
TGF-β2 and TGF-βR3 were all reduced after mimic transfection compared to the other
conditions (Figure 2.4B). However, upon examining the protein level, although both
Smad2 and Smad3 showed active phosphorylation, as is to be expected upon TGF-β
signaling, the only protein examined whose levels were decreased after mimic transfection
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was TGF-β2 (Figure 2.3D-G). Continued Smad signaling despite the reduction in TGF-β2
is likely due to persistent signaling through TGF-β1. Additionally, there was a decrease in
the amount of free-active TGF-β1 in the cells transfected with miR-466a mimic, and this
alteration was reversed with the addition of the inhibitor (Figure 2.4C).
Next, we examined the effect of miR-466a inhibition in a model wherein there was
no exogenously administered TGF-β1. To that end, naïve CD4+ cells were purified and
stimulated in vitro with anti-CD3/CD28 Ab in the presence of a locked nucleic acid (LNA),
designed specifically to inhibit miR-466a/b/c/d/e/p-3p (will be referred to as LNA-466), or
a control that was designed not to target any known miRs (LNA-ctrl). Cells treated with
LNA-466 exhibited an increase in the number of CD4+CD25HILAP+FoxP3+ Tregs
compared to controls (Figure 2.3H). To confirm that TGF-β2 can have a pronounced effect
on Treg polarization, naïve CD4 cells were polarized with either TGF-β1 (5ng/mL) or
TGF-β2 (5ng/mL). Both culture conditions induced the polarization of naïve T cells into
Tregs, but TGF-β2 induced Tregs had increased expression of inducible T-cell
costimulatory (ICOS), a marker of Treg fitness (82), compared to TGF-β1 induced Tregs
(Figure 2.3I).
miR-466a inhibitor decreases pro-inflammatory and increases antiinflammatory cells after coculture with alloantigen
To mimic more closely the in vivo environment of transplantation, we implemented
an in vitro coculture model wherein naïve LN cells were cultured with either syngeneic
antigen or alloantigen (50μg/mL). LN cells cocultured with syngeneic antigen died
between days 3-5; however, LN cells cultured with alloantigen persisted and expanded.
Coculture with alloantigen provoked a robust increase in expression of miR-466a at several
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time points compared to cells cultured with syngeneic antigen (Figure 2.5A). Next, LN
cells were cocultured with alloantigen and LNA-466 or control inhibitor and cells were
analyzed by flow cytometry. LNA-466 addition resulted in a decrease in pro-inflammatory
T helper 1 (Th1) cells that were CD4+IFNγ+, cytotoxic effector CD8+ IFNγ+ cells (Tc1),
and CD4+ IL-17A+ T helper 17 (Th17) cells (Figure 2.5B). In the same cultures, LNA466 induced increased proportions of CD4+CD25HI cells, and concomitantly increased
FoxP3+ expression among that population, compared to controls (Figure 2.5C, D).
LNA-466

attenuates

inflammatory

markers

after

allogenic

skin

transplantation
Because LNA-466 was effective in attenuating inflammatory T cells induced by
alloantigen in vitro, we investigated its effect in vivo. To that end, C57BL/6 mice were
given either C57BL/6 (syn) or C3H (allo) skin grafts and were administered LNA-466 or
LNA-ctrl at a dose of 10 mg/kg starting 1 day before allografting, and every 3rd day
thereafter, until termination of the study. While LNA-466 caused a slight delay in allograft
rejection, it was statistically not significant (Figure 2.6A). However, mice given the
allograft + LNA-466 did exhibit a significant decrease in the size and total cellularity of
draining lymph nodes, thereby indicating decreased host-versus-graft response and
inflammation (Figure 2.6B, C). In the same experiment, LNA-466 failed to induce
significant changes in the size and cellularity of the spleens (Figure 2.7A, B), thereby
demonstrating that LNA-466 was targeting the dLNs, the primary site of immune response
against alloantigen, and the site of mir-466a upregulation. To determine if LNA-466mediated effect on Tregs was having a functional impact on inflammatory cytokines, dLN
cells harvested from LNA-466-treated mice were cultured overnight and the supernatants
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were examined for cytokines. The data showed that LNA-466 derived cultures had
significantly lower effector cytokines such as TNFα and IFNγ levels when compared to
cells derived from allograft + LNA-ctrl treated mice (Figure 2.6D, E).
Mice receiving LNA-466 exhibited no significant changes in the amounts of
circulating TGF-β1; however, consistent with the ability of miR-466a to target TGF-β2,
the LNA-466 group demonstrated increases in circulating TGF-β2 when compared to syn
or allograft + LNA-ctrl groups (Figure 2.6F, G). Corroborating this finding, we found an
increase in the number of circulating memory Treg cells (Figure 2.6H, I) in the LNA-466
group, surpassing the number of memory Tregs in the syn group.
When we performed histopathological analysis of the grafts, we noted that allograft
+ LNA-466 mice showed a decrease in the levels of cellular infiltration and graft damage
compared to allograft + LNA-controls (Figure 2.6J).
LNA reduces intragraft effector cells and cytokines
Next, we directly studied the nature of cells and cytokines seen within the graft
after LNA-466 or LNA-ctrl treatment. To that end, the grafts were excised minced and
digested to retrieve graft infiltrating cells (GICs), which were either immediately stained,
or plated for 24hr in complete media to obtain GIC culture supernatants. The data revealed
that LNA-466 treated animals had a decrease in effector CD4+ and CD8+ GICs compared
to the LNA-ctrl group (Figure 2.8A-C). LNA-466 treatment also resulted in an increase in
the percentage of graft infiltrating CD4, CD62L, FoxP3+ Tregs, compared to the LNA-ctrl
group (Figure 2.8D, E). Graft culture supernatants revealed that LNA-466treatment led to
reduced levels of effector inflammatory cytokines, TNFα (Figure 2.8F) and IFNγ (Figure
2.8G), as well as increases in total TGF-β1 and TGF-β2 (Figure 2.8H & I).
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TGF-β2 induced Tregs are as potent as TGF-β1 induced Tregs in attenuating
allograft rejection response
To study the role of TGF-β2-induced Tregs in suppressing inflammation, CD4+
cells from C57BL/6 FoxP3GFP reporter mice were isolated and cultured with splenic
APCs from allogenic mice along with anti-CD3ε (10µg/mL), anti-CD28 (4µg/mL) and IL2 (10 ng/mL). TGF-β1 is conventionally used to stimulate the production of both
polyclonal and antigen-specific induced Tregs (iTregs) (4-8). Here, we tested the effect of
culture with either TGF-β1 (5ng/mL) or TGF-β2 (5ng/mL) on iTreg generation. Similar
to the polarization findings in Figure 2.3I, after 3 days of culture, we found that TGF-β2
was able to induce the generation of iTregs (Tβ2-iTregs) to the same extent and phenotype
as TGF-β1 (Tβ1-iTregs) (Figure 2.9A, B). To test the efficacy of these cells at delaying
acute rejection in vivo, after 3 days of co-culturing, iTregs were sorted for CD4+,
FoxP3GFP co-expression and 1x106 cells were intravenously injected into allograft
recipient mice 1 day before skin transplantation. Syngenic mice which did not receive any
iTregs were used as controls. Tβ2-iTregs displayed potency equivalent to Tβ1-iTregs at
delaying graft rejection (Figure 2.9C), preventing graft destruction at a rate greater than
iTregs generated without the addition of TGF-β1 or TGF-β2. iTregs were verified to be
present in the dLN (Figure 2.9D, E) to the same extent among all groups, although iTregs
induced with TGF-β1 or TGF-β2 showed greater potential to home to the allograft (Figure
2.9F, G). Indeed, grafts harvested 12 days after allotransplantation that were derived from
mice administered Tβ1-iTregs and Tβ2-iTregs showed a decrease in graft infiltrating
memory CD4+ cells (Figure 2.9H, I), and a decrease in the number of graft infiltrating
memory and effector CD8+ cells (Figure 2.9H, J). In the periphery, Tβ1-iTregs and Tβ2-
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iTregs reduced circulating CD4+ and CD8+ cells displaying a memory phenotype but did
not cause any change in circulating Tregs (Figure 2.10A-F). Lastly, Tβ1-iTregs and Tβ2iTregs could significantly reduce the number of graft infiltrating IFNγ-secreting CTLs
compared to mice which received only iTregs (Figure 2.9K, L).
2.5 DISCUSSION
Treg generation and administration is rapidly becoming a promising treatment
option for patients undergoing end-stage organ failure (3-8). Because alloantigens, unlike
conventional antigens, activate a large proportion of T cells and induce a strong
inflammatory response, we considered using this model to study the impact of such
activation on miRNA expression in T cells leading to induction of proinflammatory T cells,
while constraining Tregs. Our results provide a mechanistic perspective on how epigenetic
shifts in CD4+ T cell miRNA expression can influence the generation of Tregs by
modification of TGF-β2 expression. Our data demonstrated an upregulation of many
members of rodent miRNA cluster, C2MC, after allotransplantation in dLN CD4+ cells.
Through pathway analyses, these miRNAs, and specifically miR-466a-3p, were predicted
to target several members of the TGF-β signaling family. We showed that miR-466a
directly binds to the 3’ UTR of TGF-β2 through reporter luciferase assays. It should be
noted that while miR-466a and its target were validated in this study, there were still several
miRNA picked up by the array that were not investigated further and it is possible that such
miRNA may contribute to the complex inflammatory cascade perpetuating graft rejection.
Despite being an isoform of the widely studied TGF-β1 (11,14-15,64-68), little
information is known about the role of TGF-β2 in the immune system (67,68). Indeed,
most of the information concerning TGF-β2 is in regard to its role in development and
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function of aorta (69), Loeys-Dietz syndrome (70) and cancer (71-73). Moreover, most
studies performed involving TGF-β1 in immune cells have used TGF-βRII deficient cells
to highlight the role of TGF-β1, however, this also cancels out any potential TGF-β2
signaling. Thus, our findings that miR-466a regulates TGF-β2, which in turn plays a key
role in the generation of Tregs, are novel. This was demonstrated conclusively in our study
by altering TGF-β2 levels via transfection of CD4+ cells under Treg polarizing conditions
with miR-466a mimics, which led to decreased generation of Tregs, while mimic inhibition
reversed this effect. Furthermore, this reduction in Treg generation was associated with
decreased mRNA levels of TGF-β family members and signaling molecules Smad2/3;
however, at the protein level, while Smad2/3 showed consistent activation status between
the groups, only TGF-β2 expression was altered upon mimic transfection. The persistence
in Smad signaling despite changes in TGF-β2 expression are likely due to signaling through
exogenously administered TGF-β1 in that model of in vitro polarization. Interestingly, we
found TGF-β2 to be equally as effective as TGF-β1 at polarizing naïve CD4 cells in vitro,
even conferring increased ICOS expression to the polarized Tregs, a marker of Treg fitness
(82). To further corroborate the role of miR-466a in T cell differentiation, we used locked
nucleic acid (LNA) in a co-culture model to inhibit miR-466a expression and found that
LNA-466 caused an increase in CD4+CD25HI FoxP3+ Tregs and a decrease in proinflammatory T helper 1 (Th1) cells, CD8+ IFNγ+ cells (Tc1), and CD4+ IL-17A+ (Th17)
cells. Mice bearing allograft and treated with LNA-466 exhibited a significant decrease in
inflammation, an increase in FoxP3+ Tregs at the grafted site, and an increase in circulating
TGF-β2 and circulating memory Treg cells. Together, the current study demonstrates for
the first time that allografts induce miR-466a in CD4+ T cells which inhibits Treg
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differentiation through suppression of TGF-β2. Our data suggest that in vivo modulation
of miR-466a may constitute a novel approach to induce Tregs and thereby inhibit
inflammation that is seen in a variety of clinical disorders.
Contrary to our hypothesis that in vivo inhibition of miR-466a using LNA-466
would result in delayed allograft rejection, our data showed that LNA administration failed
to delay allograft rejection compared to controls. This may be because allografts activate a
larger proportion of T cells compared to conventional antigens, thereby provoking a more
robust inflammatory response, and the effect of LNA-466 may be too subtle to quell this
pernicious immune response in a model with such a high degree of genetic mismatch.
Moreover, in humans, HLA matching eliminates such strong host-versus-graft reactions,
which are further controlled by immunosuppressive drugs.

Nonetheless, LNA-466

administration significantly altered the immune cell environment towards a more antiinflammatory phenotype, and this was without altering the circulating levels of TGF-β1.
Despite TGF-β1 levels remaining stable in this experiment, we cannot discount the
confounding role TGF-β1 may have in these studies. Future work utilizing TGF-β1-/knockout mice will need to be performed to accurately dissect the specific impact each
TGF-β isoform is having on the generation and maintenance of Tregs. Thus, the data
presented in this study paint a picture of a complex inflammatory environment wherein
modulation of TGF-β2, specifically, via miR-466a downregulation can modify most
greatly the inflammatory environment in circulation and within the allograft.
After demonstrating how changes in TGF-β2 levels could alter Treg generation, we
investigated the role of TGF-β2 and compared it to its well-studied isoform, TGF-β1, in
Treg induction and expansion. TGF-β2 was found to be as effective as TGF-β1 at inducing
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Tregs in an allogenic coculture model. Additionally, these Tβ2-iTregs demonstrated an
ability to reduce allograft-directed inflammation at a rate comparable to Tβ1-iTregs, and
better than iTregs that were not cultured with TGF-β isoforms. This is a novel finding that
surely warrants further work – to dissect the differences, if any, between Tregs generated
via TGF-β1 or TGF-β2.
miR-466a-3p is a member of C2MC, one of the largest clusters of miRNAs,
containing 71 miRNA genes (61-63). C2MC contains subclusters 297~466~467~699,
many of which have been implicated in disease processes, from cell fate decision (76), and
apoptosis (74) to aging in the heart (75); however, most members of the 466 subcluster
have been implicated in immune regulation (76,77). C2MC is under tight, temporal and
spatial regulatory control, and exists in Sfmbt2, a region known to be imprinted (62).
Sfmbt2 is expressed preferentially in the paternal allele in early embryos, and in later stage
extra-embryonic tissue; while CpG islands spanning the transcriptional start site are
differentially methylated on the maternal allele during embryogenesis (62,63). The
developmental regulation of C2MC is especially germane to this work, because the
member of C2MC that was most highly upregulated after alloantigen exposure, miR-466a,
was found to target TGF-β2, a protein that is also under considerable governance due to its
extensive involvement in proper development (69,70). Another possible mechanism that
could be mediating the effects of TGF-β2 on the immune system, other than the direct
effect we noticed on CD4+ cells, is the effect of TGF-β2 on antigen presenting cells
(APCs). In a model of experimental autoimmune uveoretinitis (EAU) and anterior
chamber-associated immune deviation (ACAID), TGF-β2 treated APCs could provoke
antigen specific tolerance via Treg induction in vitro and in vivo (78,79). This is an exciting
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progression, and is concordant with our finding that increases in TGF-β2 levels occurred
in tandem with increased levels of Tregs, and more importantly that TGF-β2 can robustly
induce Tregs in an alloantigen coculture model. We found that purified CD4+ T cells,
draining the allograft expressed heightened miR-466a; it is quite possible these cells could
be secreting their miRNAs in exosomes as a form of cell-cell communication in the dLN
microenvironment to dendritic cells. Exosomal trafficking between CD4+ cells and DCs
has been well documented, and if CD4+ cells were secreting miRNA-filled exosomes to
decrease DC TGF-β2 expression, in accordance with the studies mentioned above, this
could result in less Tregs being induced (80). Indeed, Wilson et al. found this form of
paracrine exosomal signaling to be dominant in CD4+ cells, specifically in Treg cells (81).
Interestingly, in that same study, it was found that several members of C2MC were among
the top up-regulated miRs in Treg-derived exosomes (81). Considering clinical
transplantation involves lesser HLA incompatibilities than used in our murine model, and
due to the salutary effects in vivo manipulation of miR-466a had on allograft rejection, we
suggest that miRNA management of TGF-β2 may constitute a therapeutic modality for
allograft rejection or other inflammatory diseases - clearly additional studies are necessary
to reinforce this point. Our studies also indicate a heretofore unrecognized role for TGFβ2 in the robust induction of T regulatory cells, an observation that could be an additional
strategy for decreasing allograft rejection severity without resorting to global
immunosuppression.

30

Table 2.1 miRNA Array Analysis
Transcript ID
Mmu-miR-1291
Mmu-miR-5112
Mmu-miR-6368
Mmu-miR-7011-5p
Mmu-miR-1894-3p
Mmu-miR-6912-5p
Mmu-miR-6937-5p
Mmu-miR-6971-5p
Mmu-miR-7016-5p
Mmu-miR-7648-3p
Mmu-miR-324-3p
Mmu-miR-18a-5p
Mmu-miR-484
Mmu-miR-27b-3p
Mmu-miR-194-5p
Mmu-miR-181c-5p
Mmu-miR-128-3p
Mmu-miR-27a-3p
Mmu-miR-421-3p
Mmu-miR-19b-3p
Mmu-miR-192-5p
Mmu-miR-182-5p
Mmu-miR-let-7f-5p
Mmu-miR-30b-5p
Mmu-miR-30e-5p
Mmu-miR-21a-5p
Mmu-miR-30a-5p
Mmu-miR-15a-5p
Mmu-miR-466a-3p
Mmu-miR-466e-3p
Mmu-miR-466b-3p
Mmu-miR-466c-3p
Mmu-miR-466p-3p
Mmu-miR-669a-3p
Mmu-miR-669o-3p
Mmu-miR-467c-5p
Mmu-miR-467a-5p

Allogeneic vs.
Naive
-1.940334
-3.72864
-2.4931
-2.10665
-2.03285
-2.71246
-2.00668
-1.83436
-2.06684
-0.26363
1.729733
4.699893
2.595994
1.819848
1.819848
6.726528
4.711249
1.77744
3.317828
2.20629
4.342631
2.459444
5.910496
1.916419
2.124878
1.916419
2.191086
3.724949
2.332244
4.058871
3.908921
2.474084
2.452085
2.601293
2.129959
2.129959
2.97326

Allogeneic vs.
Syngeneic
-2.6569
-2.11819
-2.02958
-1.9088
-1.78943
-1.78591
-1.68382
-1.64353
-1.6174
-1.49674
1.5072
1.531172
1.551924
1.631183
1.631183
1.649867
1.682522
1.685586
1.855922
1.883595
1.888075
1.889462
1.890165
2.029614
2.029614
2.029614
2.09029
2.236029
2.284712
2.303314
2.445917
2.464956
2.826219
2.878352
2.955524
2.955524
2.956093
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Table 2.2 miRNA-mRNA Predicted Binding
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Table 2.3 List of Primers

Gene
Β actin

PTEN

FoxP3

TGF-β3

TGF-β2

TGF-βR1

TGF-βR3

TGF-β1

Smad2

Smad3

Primer

Sequence (5’ – 3’)

Forward

GGCTGTATTCCCCTCCG

Reverse

CCAGTTGGTAACAATGCCATGT

Forward

TGGATTCGACTTAGACTTGACCT

Reverse

GCGGTGTCATAATGTCTCTCAG

Forward

CCCATCCCCAGGAGTCTTG

Reverse

ACCATGACTAGGGGCACTGTA

Forward

AACAGCCACTCACGCACAGTG

Reverse

GCACAACGAACTGGCTGTCTG

Forward

CTTCGACGTGACAGACGCT

Reverse

GCAGGGGCAGTGTAAACTTATT

Forward

TCTGCATTGCACTTATGCTGA

Reverse

AAAGGGCGATCTAGTGATGGA

Forward

GGTGTGAACTGTCACCGATCA

Reverse

GTTTAGGATGTGAACCTCCCTTG

Forward

GAGAAGAACTGCTGTGTGCG

Reverse

GTGTCCAGGCTCCAAATATAGG

Forward

ATTCCAGAAACGCCACCTCC

Reverse

GCTATTGAACACCAAAATGCAGG

Forward

GCGTGCGGCTCTACTACATC

Reverse

GCACATTCGGGTCAACTGGTA

33

Accession
Number
NC_000071.6

NM_008960.2

NM_054039.2

NM_009368.3

NM_009367.4

NM_009370.3

NM_011578.4

NM_011577.2

NM_010754

NM_013095.3

Figure 2.1 Allografting alters the dLN T regulatory cell phenotype. Ten days after synor allografting, mice were sacrificed and organs of interest were harvested. Draining
lymph nodes (dLN) and spleens were analyzed for T regulatory cell phenotype by flow
cytometry. A Representative flow cytometry dot plots gated on CD4+ cells, displaying
the percentage of natural Tregs (nTreg) present through co-expression of CD4, FoxP3
and Nrp1 and the percentage of peripheral Tregs (pTreg) that are CD4 and FoxP3
positive, and Nrp1LO or negative. F Dot plots (lower panel) gated on CD4+, FoxP3- cells
(upper panel), displaying CD223 (LAG-3), CD49b double positive Tr1 cells. I Overlaid
histograms gated on CD4+FoxP3+ cells, displaying LAP expression. B, C, D, E, G, H
Quantification of flow cytometry results. J ELISA of total TGF-β1 in the serum of mice
on the day of sacrifice. n = 12 (Syngeneic) or 18 (Allogeneic) mice per group. Data are
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presented as mean ± SEM of three independent experiments. *P<0.05, **P<0.01,
****P<0.0001 by Student’s t-test.

Figure 2.2. Alloantigen induced miRNAs target TGF-β family members and signaling
molecules. Total RNA was extracted from purified CD4+ cells in the dLN of syn- or
allografted mice 10 days post-transplant. A Validation of microarray results through qRTPCR. B Ingenuity Pathway Analysis (IPA) of seven of the top up-regulated miRNAs and
their predicted targets. C Fold change miR-466a expression in the dLN, spleen, or
mesenteric lymph node (mLN) of purified CD4+ cells derived from syn- or allografted
mice. D qRT-PCR validation of mRNA expression changes in the dLN CD4+ cells of synor allografted mice; n = 8 (Syngeneic) or 12 (Allogeneic) mice per group. E Relative
luciferase expression in EL-4 cells transfected with luciferase reporter constructs which
contained 3′UTR of proteins of interest or a mutated 3’UTR, together with miR-466a-3p
mimics or the negative scramble control. A total of 48 h after transfection, luciferase
activity was detected. Normalized data were calculated as the quotient of Renilla/firefly
luciferase activities and are presented as mean ± SEM of three independent experiments
with 2 technical replicates indicating 6 measurements. *P<0.05, **P<0.01, ***P<0.005,
****P<0.0001 by Student’s t-test.
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Figure 2.3. miRNA 466a-3p transfection inhibits Treg polarization. Purified naïve CD4+
T cells were cultured under Treg polarizing conditions along with the indicated mimic,
control or inhibitor conditions. Cells were harvested 48 hours after addition of cytokines
and miRNA mimics, inhibitors, or controls and subject to flow cytometry, immunoblot and
qRT-PCR. Success of Treg polarization is examined as A representative dot plots, and
quantified in B and C. Representative immunoblots of indicated proteins are presented in
D and F, along with associated densitometric measurements of TGF-β2 and TGF- βR3 E,
and quantification of activated Smad 2, 3 and 4 G. CD4+ cells were purified from naïve
mouse LNs and stimulated ex vivo with CD3 (3μg/mL) and CD28 (3μg/mL) for 48 hours
and administered LNA or controls at the time of seeding. Quantification of flow cytometry
data from LAP expressing FoxP3 positive Treg cells. H Purified naïve CD4+ T cells were
cultured with either TGF-β1 (5ng/mL) or TGF-β2 (5ng/mL), along with CD3 (3μg/mL),
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CD28 (3μg/mL) and IL-2 (5ng/mL) for 5 days. I Representative dot plots of FoxP3, CD4
positive Tregs, J and their associated CD278 (ICOS) expression. Data are presented as
mean ± SEM of three independent transfection experiments. *P<0.05, **P<0.005,
****P<0.0001 by ANOVA with Tukey’s multiple comparisons test.

Figure 2.4. miRNA-466a-3p transfection in primary mouse CD4+ T Cells. CD4+ T cells
were isolated from naïve mouse LNs and purified using magnetic bead isolation. CD4+
cells were transfected with empty vector (mock), a scramble control, a miRNA-466a-3p
mimic, or an inhibitor specific to miRNA-466a under Treg polarizing conditions for 48
hours in complete media before total RNA was harvested and cell supernatants were
collected. Quantitative real-time PCR (qRT-PCR) of miRNA-466a-3p A, and indicated
mRNAs B. ELISA of free-active TGF-β1 in the supernatants of indicated groups C. Data
are presented as mean ± SEM of two independent transfection experiments indicating six
measurements. *P<0.05, **P<0.005, ***P<0.001, ****P<0.0001 by ANOVA with
Tukey’s multiple comparisons test.
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Figure 2.5. miR-466a inhibitor decreases pro-inflammatory and increases antiinflammatory cells after co-culture with alloantigen. Co-culture of LN cells with
alloantigen increases miR-466a-3p expression compared to LN cells cultured with
syngenic antigen at the indicated time points as determined by qRT-PCR A. LN cells were
administered alloantigen (50μg/mL) for 10 days in complete media. Fresh media and
miRNA inhibitors or controls were added every 3 days. Cells were harvested and stained
for Tc1, Th1, Th17 and Treg cells. B Quantitation of flow cytometry plots. C Histogram
of FoxP3 expression (bottom row), gated on CD4+, CD25+ dot plots (top row), and
quantified in D. Data are presented as mean ± SEM of two independent transfection
experiments indicating six measurements. *P<0.05, **P<0.005, ***P<0.001,
****P<0.0001 by ANOVA with Tukey’s multiple comparisons test.

38

Figure 2.6. LNA mitigates dLN effector cell and cytokines. Female C57BL/6 mice were
given either syn (BL6) or allo (C3H) tail skin grafts. Mice receiving allografts were given
either LNA-466 (10mg/kg) or LNA-ctrl (10mg/kg) i.p. 1 day before skin transplantation,
and every 3rd day after that until termination of the study. A Survival curve of mice
receiving skin transplants and indicated LNA or controls; n = 4 (Syngeneic), 7 (Allogeneic
+ Ctrl), or 8 (Allogeneic+ LNA). Draining lymph nodes were harvested twelve days after
skin transplantation from indicated groups, imaged in B and absolute cell counts were taken
in C. dLN cells were plated overnight in complete media and culture supernatants were
harvested and subjected to ELISA for TNFα D and IFNγ E. Serum was taken upon
sacrifice and subjected to ELISA for TGF-β1 F and TGF-β2 G. Dot plots of circulating
cells double positive for FoxP3 and CD62L, data are gated on CD4+ cells H, and quantified
in I. J H&E stains of grafts excised from mice upon sacrifice. Data are presented as mean
± SEM; n= at least 4 per group. *P<0.05, **P<0.005, ***P<0.001, ****P<0.0001 by
ANOVA with Tukey’s multiple comparisons test.
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Figure 2.7. Splenic inflammation after skin transplantation. Female C57BL/6 mice were
given either syn (BL6) or allo (C3H) tail skin grafts. Mice receiving allografts were given
either LNA (10mg/kg) or PBS i.p. 1 day before skin transplantation, and every 3rd day after
that until termination of the study. Image A and weight B of spleens harvested from mice
in indicated groups upon rejection of allografts. Data are presented as mean ± SEM; n= at
least 4 per group. *P<0.05, **P<0.005, ***P<0.001, ****P<0.0001 by ANOVA with
Tukey’s multiple comparisons test.
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Figure 2.8. LNA reduces intragraft effector cells and cytokines. Female C57BL/6 mice
were given either syn (BL6) or allo (C3H) tail skin grafts. Mice receiving allografts were
given either LNA-466 (10mg/kg) or LNA-ctrl (10mg/kg) i.p. 1 day before skin
transplantation, and every 3rd day after that until termination of the study. Upon rejection,
grafts were aseptically excised, minced and enzymatically digested to dislodge graft
infiltrating cells (GICs). GICs were spun down, culture supernatants were collected and
live cells were used for flow cytometric analysis. Representative dot plots displaying naïve
(CD62LLow, CD44Neg), memory (CD62L+, CD44HI) and effector (CD62LLow, CD44HI) cell
types gated on CD8+ (A, upper row) and CD4+ (A, lower row) cells. Percentages for
CD8+ and CD4+ are quantified in B and C, respectively. Dot plots of GICs double-positive
for FoxP3 and CD62L, data are gated on CD4+ cells D, and quantified in E; n = 7
(Allogeneic + Ctrl) or 8 (Allogeneic+ LNA). GIC supernatants were collected and
subjected to ELISA for the interrogation of effector cytokines TNFα F and IFNγ G, as well
as anti-inflammatory cytokines TGF-β1 H and TGF-β2 I. Data are presented as mean ±
SEM. *P<0.05, **P<0.005, ***P<0.001, ****P<0.0001 by ANOVA with Tukey’s
multiple comparisons test or a Students t-test.
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Figure 2.9. TGF-β2 induced Tregs are equally as potent as TGF-β1 induced Tregs in
ameliorating allograft rejection. CD4+ cells were purified from naïve BL6 FoxP3GFP mice
and cocultured with allogenic splenic APCs along with anti-CD3ε (10µg/mL), anti-CD28
(4µg/mL) and IL-2 (10 ng/mL). Tβ1, and Tβ2-iTregs were also administered TGF-β1
(5ng/mL) or TGF-β2 (5ng/mL), respectively. Coculture proceeded for 3 days at which
point the cells were either analyzed for FoxP3GFP expression, or sorted into
CD4+FoxP3GFP+ cells and injected intravenously into graft-recipient mice 1d before
transplantation. B Histograms of FoxP3-GFP expression gated on dot plots of
CD4+CD25+ cells in A. Female C57BL/6 mice were given either syn (BL6) or allo (C3H)
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tail skin grafts. Mice receiving allografts were administered 1x106 iTregs intravenously 1d
before transplant. Grafts were scored starting 7 days after transplantation and continued
until mice were sacrificed on day 12. GICs, dLNs and blood were collected for flow
cytometric analysis. C Survival curve of indicated groups. D, F Pseudocolor plots of GFP+,
CD4+ co-expressing iTregs in the D dLN and F among graft infiltrating cells. H
Pseudocolor plots displaying graft infiltrating CD4+ and CD8+ naïve, memory and effector
phenotypes. K Dot plots displaying IFNγ, CD8+ CTLs. Flow cytometry results quantified
in B, E, G, I, J, L. n = 5 (iTreg), 10 (Tβ1-iTreg), or 9 (Tβ2-iTreg) mice per group. Data
are presented as mean ± SEM. *P<0.05, **P<0.005, ***P<0.001, ****P<0.0001 by
ANOVA with Tukey’s multiple comparisons test, or a log-rank (Mantel-Cox) test for the
survival curve.
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Figure 2.10 Circulating inflammatory profile after iTreg administration. CD4+ cells
were purified from naïve BL6 FoxP3GFP mice and cocultured with allogenic splenic APCs
along with anti-CD3ε (10µg/mL), anti-CD28 (4µg/mL) and IL-2 (10 ng/mL). Tβ1, and
Tβ2-iTregs were also administered TGF-β1 (5ng/mL) or TGF-β2 (5ng/mL), respectively.
Female C57BL/6 mice were given either syn (BL6) or allo (C3H) tail skin grafts. Mice
receiving allografts were administered 1x106 iTregs intravenously 1d before transplant. 12
days post-transplant, mice were sacrificed and exsanguinated. A, B Zebra plots displaying
naïve, memory and effector phenotypes, gated on CD4+ or CD8+ cells. E Dot plot of
circulating Tregs. C, D, F Quantification of flow cytometry results. Data are presented as
mean ± SEM; n= at least 4 per group. *P<0.05, **P<0.005, ***P<0.001, ****P<0.0001
by ANOVA with Tukey’s multiple comparisons test.
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CHAPTER 3
CANNABINOID RECEPTOR ACTIVATION INCREASES GUT BARRIER INTEGRITY
AND INDUCES ANTI-INFLAMMATORY CD103+ DENDRITIC CELLS TO PROTECT
AGAINST COLITIS2

3.1 ABSTRACT
Intestinal homeostasis consists of the immense responsibility shared between
enterocytes and immune cells to tolerate foreign nutrients and commensal microbes, while
maintaining vigilance against pathogens. A perturbance to the coordination between host
cells and its symbionts can lead to inflammatory bowel diseases, and increased
susceptibility to colon cancer. New therapeutic approaches to prevent these disorders are
needed to attenuate their increasing global incidence. Cannabinoids are used globally for
recreational and therapeutic ends. In the current study, we demonstrate using multiple
models of colitis that Δ9-tetrahydrocannabinol (THC) was highly effective in attenuating
colitis and colon cancer. Cannabidiol when administered alone was not effective against
colitis and a combination of THC+CBD had no noticeable effect. The action of THC was
associated with stimulation of colonocyte mucin production and barrier integrity mediated
by tight-junction proteins to provide spatial separation between host and commensal

2

Becker W, Alrafas H, Nagarkatti M, Nagarkatti PS. Cannabinoid receptor activation
increases gut barrier integrity and induces anti-inflammatory CD103+ dendritic cells
to protect against colitis. Manuscript in preparation.
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organisms. In addition, THC modulated dendritic cell (DC) phenotype towards increased
CD103 expression in the colonic lamina propria (cLP) and enhanced DC TGF-β1
expression to expand the cLP Treg population, protecting the host from inflammation. Our
findings reveal THC’s salutary capacity in preventing colonic inflammation by
harmonizing the balance between colonocyte and immune cell function. 3.2
INTRODUCTION
Despite the plethora of data from pre-clinical studies on the effectiveness of
cannabinoids for IBD, only two clinical studies have been conducted, and there remains a
lack of understanding how the myriad functions of cannabinoids work collectively to
influence colitis development and progression (53-56). We set out to garner a holistic view
of the gut macroenvironment after cannabinoid administration. To accomplish this, the
most commonly used cannabinoids, THC and CBD, were used alone or in tandem in
several murine models of colitis with disparate etiologies to investigate how the gut
immune cells, intestinal barrier, and gut flora work synergistically after cannabinoid
treatment to prevent colitis.
3.3 MATERIALS AND METHODS
Mice The University of South Carolina Institutional Animal Care and Use
Committee approved all experiments. All mice were housed at the AAALAC-accredited
animal facility at the University of South Carolina, School of Medicine (Columbia, SC)
under specific pathogen-free conditions and 12 hr dark/light cycles in temperaturecontrolled rooms and given ad libitum access to water and normal chow diet. Female
C57BL/6 and BALB/C mice, aged 8-12 weeks were obtained from Jackson Laboratories
(Bar Harbor, ME, USA). Cnr1-/-, Cnr2-/-, and double knockout Cnr1-/-Cnr2-/- mice are
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on a C57BL/6 background and were bred and maintained in-house. The number of mice
for each experimental cohort is described in the Figure legends.
Colitis induction and treatments For all colitis experiments, unless otherwise
indicated, treatments began three days before disease induction with CBD (10mg/kg), THC
(10mg/kg) or a combination of THC+CBD (10mg/kg, both), or the vehicle control
(ethanol). All treatments were suspended in ethanol and delivered to animals as a ratio of
2:1:18 ethanol:Tween-80:PBS by oral gavage. For the induction of TNBS-induced colitis,
BALB/C mice were anesthetized by light isofluorane administration and given an
intrarectal administration of 100 μL of 1mg of TNBS (Millipore, Sigma) dissolved in 50%
ethanol. Mice were kept vertical for 30s after TNBS administration to keep the TNBS in
contact with the colonic mucosal surface. DSS colitis was induced by dissolving 2% DSS
(MP Biomedicals) in the drinking water and giving mice ad libitum access until the end of
the study or humane endpoints were reached. To induce anti-CD40 colitis, mice were
injected i.p. with 100 μL of 200 μg of anti-CD40 IgG2a monoclonal antibody (clone
FGK4.5) or isotype rat IgG2a control (both from Bio X Cell), dissolved in PBS. Studies
examining the effects of Treg depletion on anti-CD40 colitis progression proceeded as
above but with an i.p. injection of rat anti-mouse CD25 (clone PC61, 100 mg/kg) or isotype
control (both from Biolegend) one day before anti-CD40 injection.
Assessment of colitis disease parameters For all colitis models, mice were weighed
daily, and colon lengths were measured at experimental end-points. Stool scores were
measured according to a modified stool scoring system (Table 3.1). Colonoscopy images
were taken at indicated time points by anesthetizing the mice and using a high-resolution
mouse endoscopic system Karl Storz (Tuttlingen, Germany) Tele Pack Vet X LED
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endoscope designed for small animals. The severity of colitis was scored using the mouse
endoscopy and murine endoscopic index of colitis severity (MEICS) system, detailed in
(Table 3.2). To investigate the levels of proteins clinically relevant to the diagnosis of
colitis severity, mice were sacrificed, and blood was taken via the portal vein, allowed to
clot, and serum was taken after centrifugation. Serum samples were subjected to sandwich
ELISAs for Serum amyloid A (SAA; Abcam), Lipocalin-2 (LCN-2; Invitrogen) and
Myeloperoxidase (MPO; Invitrogen), according to manufacturer’s instructions.
AOM/DSS model of colitis-induced colorectal cancer C57BL/6 mice aged 8-10
weeks old were injected i.p. with azoxymethane (AOM, MPBIO) (10mg/kg). DSS (1%)
was added to the drinking water one week after AOM administration for one week before
regular drinking water was returned for two weeks. Three of these DSS (1%)-regular water
cycles were completed before mice were kept on regular water and monitored for polyps
via colonoscopy until sacrifice. Treatments with VEH, THC (10mg/kg) or THC/CBD
(10mg/kg, both) began one week after administration of AOM and continued twice weekly
until the end of the last DSS cycle.
Gut permeability assay On day 2 of TNBS-induced colitis, and day 9 of DSSinduced colitis, mice had their food and water removed in the evening. The next morning,
mice were gavaged with 600 mg/kg of 4kD FITC-dextran (MilliporeSigma) in 100 μL
PBS. Food and water were returned, and 4 hours later, blood was collected by retroorbital
bleeding, blood was allowed to clot, and serum was separated after which FITC-dextran
concentrations were determined using a PerkinElmer Life Sciences (Boston, MA)
spectrophotometer with excitation wavelength at 480 nm.
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Histology Proximal colon tissues were excised, rinsed with PBS and fixed by
immersion in 3% paraformaldehyde (PFA) for 24 hours. Fixed tissues were embedded in
paraffin, sectioned and stained with hematoxylin and eosin. For Periodic Acid-Schiff
(PAS) staining, a staining kit purchased from MilliporeSigma was used following
manufacturer’s instructions. Color bright field images and picture montages were taken
using a Cytation-5 Imaging Reader (BioTek Instruments, Winooski, VT, USA).
Tissue Processing Mesenteric lymph nodes (MLNs) and spleens were excised and
brought to a single cell suspension. Spleens were subjected to red blood cell lysis before
both spleens and MLNs were passed through a 70 μM filter, spun down and re-suspended
in FACS buffer for flow-cytometric analyses.
To isolate the colonic lamina propria (cLP), colons were excised and luminal
contents were removed by gliding curved forceps down the length of the colon, colons
were opened longitudinally and mucus was removed by gentle scraping in sterile 1X PBS.
Tissue was cut into 0.5 cm pieces and incubated in pre-warmed sterile 1X HBSS (without
Ca2+ and Mg2+) containing FBS (3%vol/vol), 10mM EDTA (Cellgro), and 5mM DLDithiotreitol (DTT; MilliporeSigma) for 30 minutes at 37°C while shaking. The intraepithelial cells (IECs) containing immune cells and enterocytes were recovered by filtering
the colon pieces over a 100μM filter. The supernatant containing the IEC fraction was put
on ice for at least 10 minutes to allow sedimentation of debris, and the IEC fraction was
taken from the upper part of the supernatant. Remaining tissue containing the cLP was
incubated in pre-warmed 1X HBSS (with Ca2+ and Mg2+) solution (15mL/colon)
containing FBS (3%vol/vol), 1% L-glutamine, 1% penicillin–streptomycin, 10 mM
HEPES, 0.5 mg/mL collagenase D (Roche), 0.5 mg/mL Dispase (MilliporeSigma) and 0.04
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mg/mL DNase I (MilliporeSigma) for 45 minutes at 37°C while shaking. The supernatant
was filtered over a 70μm cell strainer into ice cold sterile 1X PBS. cLP cells were passed
through a Percoll (GE Healthcare) gradient (40%/80%(v/v) gradient) and spun at 620xg
for 20 minutes with low acceleration and no brake. Cells at the 40/80 interface were
collected and washed twice with supplemented FACS buffer and prepared for flow
cytometric analysis.
Flow cytometry Relevant tissues were brought to a single cell suspension, then 1-2
x 106 cells were washed with PBS and then stained with Live/Dead Fixable Aqua Dead
Cell Stain Kit (Invitrogen) for 30 minutes at 4°C to aid in excluding dead cells. Cells were
then washed and incubated with TruStain FcX anti-mouse CD16/32 (Biolegend) to block
Fc receptors. Extracellular antigens were stained for 20 minutes at room temperature in
staining buffer. Cells were fixed and permeabilized with BD Cytofix/Cytoperm (for
cytokine restimulations) or BD Transcription Factor Buffer Set (for transcription factor
staining) per manufacturer’s instructions. Intracellular antigens were stained for 1 hour at
4°C in the appropriate 1x Perm/Wash buffer. Cells were washed with staining buffer and
passed through a 100 μm nylon mesh before acquisition on a BD FACSCelesta (Becton
Dickinson). Analysis was performed using FlowJo software (FlowJo, BD). All samples
were recorded based on the same live cell threshold per tissue. Compensation was set using
fluorochrome labeled CompBeads (BD Biosciences). Fluorochrome-conjugated antibodies
are detailed in Table 4.
Cell culture and in vitro treatments Cells were cultured in a sterile incubator
maintained at 37°C and 5% CO2. Caco-2 and LS174T cells were obtained from American
Type Culture Collection (ATCC; Manassas, VA), while MC-38 cells were obtained from
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Kerafast (Boston, MA). Cells were cultured in Dulbecco’s Modified Eagle Medium
(DMEM; Life Sciences) supplemented with 10% fetal bovine serum, 100 U/mL penicillin
and 100 U/mL streptomycin, 1% (v/v) non-essential amino acids and 10mM HEPES (all
Gibco, Paisley, UK). For experiments involving the addition of compounds, all cell lines
were used at a population doubling (PD) between 10-20. Cells were seeded at 0.5 x 106
cells/well in a 6-well plate. Upon ~80% confluence, media was removed and replaced with
media containing vehicle with THC, CBD, AM251, SR144528 or a combination (all at
10μM). Primary cells were cultured in complete RPMI supplemented with 10% FBS, 100
U/mL penicillin, 100 U/mL streptomycin, 10mM HEPES (Gibco, Paisley, UK), and 50 μM
β-mercaptoethanol (MilliporeSigma, Gillingham, UK) (complete medium).
Bone marrow dendritic cell generation and DC: T cell coculture Naïve bone
marrow cells were collected from the femurs of 10-week-old C57BL/6 mice and plated at
a density of 1x106 cells/mL in 24-well plates with GM-CSF (20ng/mL) and IL-4 (10
ng/mL) supplementation to generate bone-marrow dendritic cells (BMDCs). 18 hours after
initial plating, debris and non-adherent cells were removed and media containing GM-CSF
was replaced and cells were monitored for 7 days until the end of culture. VEH or THC
(10µM) were added to wells at initial plating and at media changes. On day 7, floating cells
were collected and analyzed by flow cytometry, recovered supernatants were subjected to
ELISA for TGF-β1. On day 6, floating cells were collected and DCs were purified by
magnetic sorting for CD11c (EasySep, STEMCELL Technologies). Some purified DCs
were re-plated in complete media for another day before supernatants were collected.
Concurrently, naïve C57BL/6 mice were sacrificed, spleens and lymph nodes were
harvested and brought to a single cell suspension before CD3+ T cells were isolated via
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magnetic sorting and pulsed with CFSE (5µM). CD11c purified BMDCs treated with VEH
or THC were plated with naïve T cells in 48-well plates at a ratio of 1:5 DCs to T cells with
either 50 µg IgG control (Biolegend) or 50 µg anti-CD40 (BioXCell). Co-cultures
continued for 3 days and select wells were harvested daily for examination of T cell
proliferation.
RNA extraction and qPCR After isolation and purification, tissues of interest were
snap frozen in liquid N2, or placed in RNAlater (Qiagen) and transferred to -80°C until
ready for processing. Total RNA was isolated using RNeasy kit (Qiagen). Quality and
quantity of RNA was determined by Nanodrop 2000 or Qubit fluorometer (both
Invitrogen). Lithium chloride precipitation was carried out on tissues derived from DSStreated mice to remove DSS contamination from RNA samples according to (100). Total
RNA was used to make cDNA using miScript cDNA synthesis kit from Bio-Rad. qRTPCR was carried out using SsoAdvanced SYBR green supermix from Bio-Rad. All qRTPCR experiments were carried out on a CFX96 (or 384) Touch Real-Time PCR Detection
System (Bio-Rad), using two-step amplification with a 60°C annealing temperature.
Expression levels were normalized to 18S mRNA levels in mouse tissue samples; samples
derived from MC38 cells were normalized to a combination of β-actin and 18S expression.
Caco-2 samples were normalized to a combination of B2M and RPLPO expression, based
on (101) and stable expression between treatment groups. Fold changes were calculated
using the 2-ΔΔCT method. Primers for genes of interest are detailed in (Table 3.3).
Short Chain Fatty Acid Quantification using GC-MS At sacrifice, cecal contents
were snap frozen in liquid N2 until ready for processing. Cecal contents were weighed and
homogenized in ultrapure water to a concentration of 250 mg/mL. 1:4 volumes of 25%
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metaphosphoric acid was added to samples for 30 minutes on ice. Acidified samples were
centrifuged at 12,000xg for 15 minutes at 4°C before filtering the supernatant over Ultrafree MC columns (MilliporeSigma) using the same spin. An internal standard (IS) of 2ethylbutyric acid was added to all samples and standards at a concentration of 0.1mM
before addition of methyl tert-butyl ether (MTBE). Acidified and filtered samples with IS
and MTBE were vortexed, spun down at 200xg for 5 minutes at room temperature, and the
organic layer was recovered and subjected to a HP 5890 gas chromatograph configured
with flame-ionization detectors (GC-FID). Stabilwax®-DA Column (fused silica) of 30 m
× 0.32 mm i.d. coated with 0.50 μm film thickness was used. Helium was supplied as the
carrier gas at a flow rate of 15 mL/min. The temperature was programmed to achieve the
following run parameters: initial temperature 100°C, hold for 0.5 min, ramp 20°C/min,
final temperature 250°C, maintain for 5 min. The injected sample volume for GC analysis
was 1 μL splitless and the total run time was 18.0 min. Calibration standards were prepared
as aqueous stock solutions using these fatty acids at the given concentration; acetic,
propionic, and n-butyric at 400 mM, isovaleric and valeric 200 mM, isobutyric 100 mM,
caproic and n-heptanoic 50 mM (all from MilliporeSigma). Each standard was injected to
identify their retention times. Standard mixture was prepared at several concentrations
suitable for the samples. Response factors (RF) were calculated via dividing the peak areas
of the responses by the respective concentrations of the standards. To quantify the peak
area in terms of concentration, the relative response factor (RRF) was used. The RRF was
calculated using the formula RRF = RFStandard/RFIS. The concentration of the samples
was calculated using the following equation, Conc. samples = Peak AreaSample x (Conc.
IS/ Peak AreaIS)(1/RRF).
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Antibiotic treatment BL6 mice were randomized and subjected to antibiotics in
their drinking water for at least 3 weeks. Antibiotics included: ampicillin (1g/L),
metronidazole (1g/L), neomycin (1g/L) and vancomycin (0.5g/L). Fresh antibiotic water
was replaced every week. At the end of the antibiotic treatment, stool was collected, DNA
was extracted, and PCR using Eubacteria primers was conducted and analyzed via agarose
gel electrophoresis to determine extinction of bacterial DNA from post-antibiotic treated
mice compared to pre-antibiotic mice. Fecal transfer donor mice (3-4 per group) were given
at least three administrations of THC (10mg/kg) or vehicle before being moved to clean
cages. After finishing their antibiotic regimen, recipient mice were then randomized again
and placed into the old donor mouse cages with their used bedding. Three days after the
end of antibiotic treatment, donor mice were placed in clean cages, stool was collected and
re-suspended in PBS to 120mg of feces/mL of sterile PBS. Stool was homogenized by
vortexing and shaking and spun down at 800xg for 6 minutes at room temperature.
Supernatant was passed through a 40μM filter and administered to recipient mice in 200μL
by oral gavage for 3 days before beginning DSS colitis.
16S Sequencing Fecal pellets were collected on indicated days and stored at -80°C.
For isolation of mucus-associated bacteria, colons were excised upon sacrifice, luminal
contents were removed, colons were opened longitudinally and gently rinsed in a petri dish
with PBS. Mucus was then scraped from the luminal surface of the colons and stored at 80°C. Colon-associated bacteria was harvested by taking a ~1cm piece of the proximal
colon after the mucosal lining was removed and snap freezing it in liquid N2. Bacterial
DNA was extracted using the QIAamp Fast DNA Stool Mini Kit (Qiagen). Doublestranded DNA was quantified by Qubit Fluorometer (Invitrogen). Primers for the V4 region

54

of the 16S rRNA bacterial gene were used for amplification, then samples were
individually barcoded to label each sample according to Illumina 16S Sample Preparation
Guide (Illumina). Amplified 16S rDNA was sequenced using Illumina MiSeq. Sequence
data were processed using QIIME. Read pairs were quality filtered and joined to form a
complete V4 amplicon sequence. Operational taxonomic units (OTUs) were selected by
clustering reads at 99% sequence similarity in relation to the Greengenes reference
database using the consensus method implemented in QIIME.
Statistical Analyses Data were analyzed using GraphPad Prism software with the
statistical test and number of experimental repetitions indicated in the respective Figure
legends. Unless otherwise stated, data are presented as individual dots for each
sample/mouse, a line for mean, and bars indicating SEM. Tests were always 2-sided where
applicable; P < 0.05 was considered significant.
3.4 RESULTS
Cannabinoids ameliorate TNBS-induced colitis and reduce effector cell
phenotypes.
We investigated the beneficial effects of cannabinoids on intestinal inflammation
by examining a murine model of acute colitis that mimics the human symptoms of
ulcerative colitis. BALB/c mice were injected intrarectally with 100 mg/kg of 2,4,6Trinitrobenzenesulfonic acid (TNBS) in 50% ethanol. To test if cannabinoid treatment
would prevent the onset of the diseases, we initiated the treatment 3 days before disease
induction. We used 4 groups of mice: TNBS+Vehicle, TNBS+CBD, TNBS+THC and
TNBS+THC+CBD. We used 10mg/kg of THC or CBD or 10 mg/kg each of THC and
CBD in the combination group. We used THC+CBD because these cannabinoids are found
together in Cannabis and may offer beneficial effects when combined.
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THC and

THC+CBD treatment was able to reduce the body weight loss compared to VEH control,
while CBD alone failed to reduce weight loss (Figures 3.1A, B). Colonoscopy revealed
significant inflammation, bleeding and ulcers in the VEH and CBD groups, which was
diminished in the THC and THC+CBD groups (Figure 3.1C, 1D, 3.2A). The VEH group
had significant colon shortening attenuated with THC or THC+CBD treatment but not with
CBD alone (Figures 3.1E, F). Inflammatory markers including serum Amyloid A (SAA),
Lipocalin-2 (LCN2) and Myeloperoxidase (MPO) were all reduced in the THC or
THC+CBD group mice, when compared to vehicle controls, with less striking effects in
MPO levels, while CBD alone failed to have significant effect (Figures 3.1G-I). Periodic
acid-Schiff’s staining showed that VEH and CBD groups had significant tissue damage,
more immune cell infiltration, and less mucus deposition compared to THC and
THC+CBD groups (Figure 3.1J). To characterize the immune cell populations, the colonic
lamina propria (cLP) cells were subjected to flow cytometric analysis. Gating strategy are
detailed in (Figures 3.2B-E). THC and THC+CBD reduced the number of CD8+IFNγ+
cytotoxic T cells (CTLs) compared to VEH and CBD groups (Figures 3.1K-, L). There was
no change in CD4+ IL-17A secreting Th17 cells (Figure 3.1L, M); however, THC and
THC+CBD increased the FoxP3+ T regulatory cells in the cLP compared to VEH and CBD
groups (Figure 3.1O, P). Overall, these data demonstrated that while CBD alone at the
dose tested (10mg/kg) was not effective in attenuating TNBS-mediated colitis, THC or a
combination of THC+CBD were highly effective. Also, THC alone was as effective as
THC+CBD.

56

Cannabinoids prevent DSS-induced colitis and reduce effector cell
phenotypes.
Due to the success of THC and THC+CBD in ameliorating TNBS-induced colitis,
we next sought to investigate how cannabinoids may benefit a model of colitis with a
different etiology, dextran sodium sulfate (DSS)-mediated colitis. C57BL/6 mice were
treated with VEH or cannabinoids for 3 days before disease induction via 2% DSS in the
drinking water and body weight, stool parameters and colonoscopies were performed
periodically throughout the 13-day disease course. THC or THC+CBD were efficacious at
preventing weight loss and bloody diarrhea when compared to VEH controls while CBD
alone was not effective (Figures 3.3A, B; 3.4B). The colonoscopies revealed less
inflammation and a thicker mucus layer in the THC and THC+CBD groups than the VEH
and CBD groups throughout the study (Figures 3.3C, D; 3.4A). Colon lengths were
measured at sacrifice and provided further evidence of the disease-preventative effects of
THC and THC+CBD (Figures 3.3E, F), bolstered by the serum biomarkers SAA and LCN2 that were also reduced in treatment groups (Figures 3.3G, H), while MPO was not (Figure
3.3I). Overall, CBD alone was ineffective except for reducing SAA (Figure 3.3G). PAS
stains of the proximal colon exhibited prominent immune cell infiltration in the VEH and
CBD groups and decreased mucus production from goblet cells which was reversed in the
THC or THC+CBD groups (Figure 3.3J). Flow cytometry of cLP effector immune
populations revealed a reduction in the THC and THC+CBD groups of inflammatory Th17
cells, CD8+IFNγ+ cells (Figures 3.3K-N), and an increase in Tregs (Figure 3.4C, D).
Additionally, we found a reduction in T-bet+ Th1 cells but no significant change in Gata3+
Th2 population in THC or THC+CBD groups when compared to VEH group (Figure 3.3O,
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P). Overall, these data are consistent with the findings from the TNBS-induced colitis
model in that while CBD alone was not effective in attenuating DSS-induced colitis, THC
alone or a combination of THC+CBD was highly effective. Also, THC was as effective as
THC+CBD suggesting that CBD, at the dose tested, provided no additional benefit.
Cannabinoid receptor 1 activation leads to increases in gram-negative bacteria
and short-chain fatty acid dysregulation that are inconsequential to DSS progression.
To examine whether the anti-colitic effects of cannabinoids such as THC are due
to any changes in the gut flora, we first performed studies using naïve mice. Stool was
collected from a pool of naïve mice before (Pre-Tx) and after five administrations of either
VEH (VEH 5X) or THC (THC 5X, 10 mg/kg, oral gavage), DNA was extracted and 16S
rRNA sequencing was performed. Short-term THC administration, compared to Pre-Tx
mice and VEH 5X mice, showed increases in gram-negative Bacteroidetes and
Proteobacterial phyla (Figures 3.5A-C). The specific Proteobacteria altered after THC
administration belonged to the classes alpha- and gammaproteobacteria (Figure 3.5D). To
assess how acute (1X) and short-term (5X) THC administration altered levels of bacterial
metabolites heavily implicated in homeostatic host functioning, analysis of short-chain
fatty acids (SCFAs), was performed on the cecal contents. The data showed an increase in
acetate and butyrate 24 hours after a single (1X) administration of THC compared to VEH
(Figure 3.5E), however, this increase was transient, as there were no differences in cecal
SCFA levels after short-term (5X) THC administration (Figure 3.5F). To identify if
changes in gut microbiota were mediated through cannabinoid (CB) receptors, CB1 (Cnr1/-), CB2 (Cnr2-/-) or double CB receptor knockout (Cnr1-/-Cnr2-/-) mice were utilized.
Administration of THC 5X in Cnr2-/- mice led to similar bacterial community changes as
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seen in WT mice, with an increase in the THC 5X group of bacteroides and
gammaproteobacteria, suggesting a CB2-independent mechanism through which they are
increased (Figure 3.5G). Despite similar changes in bacterial composition in Cnr2-/- and
WT mice given THC, Cnr2-/- mice given THC short-term had reduced levels of butyrate
in their cecal contents (Figure 3.5H), and this was not seen after acute administration
(Figure 3.6A). In Cnr1-/- mice given THC, we saw an opposite trend wherein THC, acutely
and after short-term administration, reduced acetate and proprionate levels in the cecum
(Figures 3.6B, C), and short-term THC administration led to increases in gram-positive
Firmicutes classes (Figure 3.6D). Notedly, it is through the CB receptors that THC exerts
its flora-altering effects, because short-term THC administration in Cnr1-/-Cnr2-/- mice
showed inconsequential effects on bacterial community shift or SCFA production
compared to VEH or Pre-Tx mice (Figures 3.6E, F).
Next, we investigated how cannabinoids impact the microbial balance in the DSSinduced colitis model. We found that despite some overlap between all groups, the THC
and THC+CBD group, in which colitis was attenuated, were clustered closer together and
farther away from the VEH and CBD groups, that developed severe colitis (Figure 3.5I).
Concordantly, the THC and THC+CBD groups had higher levels of acetate, proprionate
and butyrate in their cecal contents when compared to the VEH and CBD groups (Figure
3.5J). To test whether the changes in bacterial community seen with THC administration
are the mechanism of protection against colitis development, we did a fecal transfer (FT)
experiment wherein naïve mice were given antibiotics (ABX) in their water for 4 weeks to
deplete their microbiota. Then they were taken off ABX water and placed in cages with the
used bedding of mice that had received short-term VEH or THC administration which
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would be the FT donor mice. After 3 days in the used cages with regular drinking water,
stool from donor FT mice was collected freshly and gavaged to recipient mice for 3 days
before giving DSS and then for another 5 days after giving DSS. Weight loss was
monitored and the data revealed that the fecal bacterial community from THC treated mice
could not protect mice from colitis (Figure 3.5K).
Cannabinoids utilize both cannabinoid receptors to specifically increase
colonic barrier integrity and mucus production to protect against colitis induction
Because barrier integrity plays a critical role in colitis, we investigated the effect of
cannabinoids on this property. On the last day of DSS colitis (day 12) and TNBS colitis
(day 4), mice were gavaged with 4kD FITC-Dextran and 4 hours later, serum FITCDextran levels were analyzed as a measure of gut permeability. The data showed that
cannabinoids were ineffective at reducing gut permeability induced by DSS colitis,
compared to VEH group (Figure 3.7A); however, in the TNBS colitis model, both THC
and to a lesser extent THC+CBD reduced the gut permeability caused by TNBS (Figure
3.7B). To resolve this incongruity, we recalled that the THC and THC+CBD groups in both
DSS and TNBS colitis models evinced increased mucus production via both colonoscopy
imaging and PAS staining. To substantiate, mice were given acute or short-term VEH or
THC administration, and proximal colons were harvested 24 hours later, and PAS stains
were performed to assess mucus deposition in the colonic lumen. We observed a striking
increase in mucus emanating from the goblet cells in the THC 1X group into the lumen,
that while reduced in vibrance in the 5X THC administration group, was still noticeably
increased in the lumen at that time point compared to VEH (Figure 3.7C). We then
considered the nature of the DSS and TNBS models and how the DSS model of Crohn’s
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disease instigates inflammation throughout the entire GI tract, while TNBS colitis is more
restricted to the colonic epithelium, akin to ulcerative colitis. Thus, we looked at mucus
and tight-junction protein expression in the proximal colon (PC) and small intestine (SI) in
VEH (1X) or THC (1X) mice and found that THC increases mRNA expression of gelforming Muc2 and Muc5ac specifically in the PC (Figure 3.7D). Similarly, increases in
tight-junction proteins: Claudin and Zonula occludens-1 (ZO-1), but not Occludin, were
specifically seen in the PC after acute THC treatment (Figure 3.7D). Given that mucin
expression and the regulation of anti-microbial peptides, β-defensins, are intertwined
(95,96), we then examined β-defensin 1 and 3 expression and found that it was also
increased after short term THC administration, and specifically in the PC, not in the SI
(Figure 3.7D). We tested whether the observed expression increases persist in situations of
DSS-induced inflammation and found THC, but not CBD, increases the colonic expression
of Muc2, Muc5ac, ZO-1 and β-Defensin 3 (Figure 3.7E). Moreover, this effect was
observed in the mouse MC38 adenocarcinoma cell line (Figure 3.7F). Treating the human
adenocarcinoma cell line, Caco-2 with THC and CB antagonists AM251 (CB1) and
SR144528 (CB2) revealed THC-mediated increases in ZO-1 were through CB1, as they
were reduced in the THC+AM251 group (Figure 3.7G). Contrary to the work in mice, βDefensin 1 expression was reduced by THC and was dependent on both CB receptors
(Figure 3.7G). THC administration to Caco-2 cells was able to increase Muc2 and Muc5ac
expression in this cell line, and this is also dependent on both CB receptors, because only
with a combination of AM251 and SR144528 are expression levels returned to the level of
the vehicle (Figure 3.7G). Further evidence that THC requires both CB receptors to
increase mucus and defensin production is mirrored by work in Cnr1-/- and Cnr2-/- mice
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where THC has no effect (Figure 3.6G). To approximate how the increased colonocyte
barrier integrity caused by THC effects disease initiation and prevention, TNBS and DSS
colitis models were initiated as was done previously, but with a THC pre-treatment group
(Pre-Tx), that began receiving treatment 3 days before disease initiation, and a treatment
group (Tx), that received treatment concurrently with disease initiation. Although both
methods display efficacy in reducing disease parameters, THC pre-treatment was
significantly more effective than concurrent treatment at preventing colitis in both TNBS
and DSS-colitis models as evidenced by a decrease in weight loss and colon shortening
(Figure 3.7H-K).
THC treatment reduces αCD40 colitis severity through a reduction in
dendritic cell activity.
TNBS and DSS-induced colitis result from luminal damage to the enterocyte layer,
while anti-CD40 Ab injection is known to trigger colitis resulting from robust intestinal
inflammation stemming from the macrophage and DC activation (97,98). Importantly, this
model acts solely on the immune system, and is independent of the microbiota or intestinal
permeability to stimulate inflammation (93,97,98). To study the effect of cannabinoids in
this model, 3 days before disease induction, we began treatment with VEH or THC as done
in previous colitis models, and then a single injection of αCD40 Ab or IgG control Ab was
administered intraperitoneally (ip). Disease severity peaked 3 days post αCD40 Ab
injection and treatment continued until 7 days post disease-induction at sacrifice. Both
VEH and THC treated mice lost significant weight compared to IgG controls, some losing
up to 15% in 3 days; there was no ameliorative effect of THC on weight loss caused by
disease (Figure 3.8A). However, spleen weight used as a marker of systemic inflammation
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and mesenteric lymph node cellularity, were both significantly reduced by THC treatment
(Figures 3.8B, C).

THC treatment was also able to reduce levels of serum pro-

inflammatory cytokines, IFNγ and TNFα (Figure 3.8D). In this model, the levels of Th2
cytokines such as IL-4, IL-5, and IL-13 were low and remained unchanged after THC
treatment. Colonoscopy at peak of disease on day 3 also revealed decreased inflammation
in the THC treated group when compared to VEH group, and once again noticeable mucus
deposition was seen in the lumen of THC treated mice (Figure 3.8E, F). Immune cell
phenotyping in the cLP showed a decrease in the percentage and numbers of infiltrating
CD45+ immune cells in THC group when compared to VEH group (Figures 3.8G-I). Also,
there were less cLP macrophages in the THC treated group (Figures 3.8J, K); however,
there was no difference in the activation markers CD80 or CD86 on the macrophages
(Figures 3.9A, B). Dendritic cells (DCs), by comparison, were not reduced in percentage
in the cLP (Figures 3.8L, M), but their levels of activation marker CD80 were reduced in
the THC group (Figures 3.9C, D). In the mLN, THC treatment reduced IFNγ secreting
CD8+ cells and CD4+ Th1 cells, when compared to VEH (Figures 3.9E-H), while there
were no observed differences in CD4+ IL-17A, IL-10 or IL-4 secreting cells, or in DC
phenotype (Figures 3.9I-L). To assess how cLP DCs played a role in disease, we
characterized the subsets of DCs known to heavily influence intestinal inflammatory
balance. We phenotyped DCs for their expression of surface markers CD103 and CD11b,
because DCs with higher expression of CD103 have been shown to play a role in promoting
an anti-inflammatory response through Treg induction (88), whereas DCs with more
CD11b expression are catalysts for T cell and innate lymphoid cell (ILC) inflammatory
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responses (99). THC treatment caused an increase in CD103+ DCs and a concurrent
decrease in CD103+CD11b+ DCs at sacrifice compared to VEH mice (Figure 3.8N, O).
Dendritic cell re-programming and not Treg induction are the mechanism
through which THC ameliorates αCD40-induced inflammation.
Considering the observed DC phenotype switch, we examined the numbers of
Tregs in the cLP of αCD40 and IgG control mice after VEH or THC administration. Flow
cytometric analysis of Treg phenotype revealed that αCD40 Ab treated mice had an
increase in Helios+FoxP3+ natural Tregs (nTregs), when compared to control mice, and
THC treatment further enhanced this population (Figure 3.10A, B). Because an increase in
FoxP3+ Tregs was seen in the TNBS and DSS model as well after THC and THC+CBD
treatment, we considered this as a possible mechanism through which THC exerts its anticolitic effects. However, depleting Tregs using an anti-CD25 antibody (clone PC61, 100
mg/kg) one day before disease induction with αCD40, proved to be an unlikely mechanism
through which THC acts, as there was no change in the body weight loss or spleen weight
between αCD40 mice treated with THC with or without an intact Treg pool (Figures 3.10C,
D). In the TNBS, DSS and αCD40 models, we observed a THC-mediated phenotypic
change towards increased DC CD103 expression (Figure 3.11A-D). Therefore, we shifted
our focus back towards THC’s effects on DCs and looked at how THC affects intestinal
DCs acutely, in situations without overt inflammation. Acute (1X) THC treatment
increased the percent of CD103+ single positive and reduced the percent of
CD103+CD11b+ double positive DCs in the cLP 24 hours after a single THC
administration (Figure 3.10E, F). One mechanism through which CD103+ DCs can
influence Treg induction is through TGF-β1 secretion (88), and supernatants recovered
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from cLP cells harvested from THC or VEH 1X mice and plated overnight revealed a trend
towards increased TGF-β1 production in THC-treated mice (Figure 3.10G). The increase
in CD103+ DCs seen in the cLP after THC administration was not noticed in the mLN of
these mice (Figure 3.10H, I), and the increase in TGF-β1 seen in the cLP after THC
treatment was also not seen in the mLN (Figure 3.10J), suggesting a cLP specific effect.
Because DCs traffic between the cLP and mLN, their temporal and spatial activity after
THC treatment is important to understand their functioning. CCR7 expression is linked to
trafficking between the mLN and cLP (98), therefore, we looked for CCR7 expression on
cLP and mLN DCs after THC 1X exposure and found that THC acutely reduced DC CCR7
expression in the cLP but especially in the mLN (Figure 3.10K, L), suggesting that DCs
were migrating less between the immune tissues in the intestines. To isolate the effects of
THC on DCs specifically, bone-marrow dendritic cells (BMDCs) were generated by
addition of GM-CSF and IL-4 to a culture of naïve bone marrow cells treated with VEH or
THC. The data showed THC treated BMDCs had more TGF-β1 in their supernatant when
compared to controls (Figure 3.10M). Although there were equivalent percentages of DCs
in the VEH and THC treated cultures, a BMDC culture is a mixed population of cells, and
thus on day 6 of BMDC culture, CD11c+ DCs were purified and plated overnight, and
analysis of their supernatant revealed that TGF-β1 levels were increased from the THCtreated BMDCs compared to VEH controls (Figure 3.10N). We observed a decrease in DC
CD80 expression, but not CD86 expression in THC treated cultures; and THC-treated DCs
reduced CD4 and CD8 T-cell proliferation in vitro (Figures 3.11E-G). Furthermore, THC
administration increases the number of cLP Helios+FoxP3+ nTregs in a CB2 dependent
manner, and while DC phenotype is consistent between knockout and WT mice, there are

65

significantly reduced numbers of total DCs in the cLP of Cnr2-/- mice (Figure 3.12A-D).
Next, we analyzed other immune cell changes that occur after acute THC administration
under naïve conditions and found that THC does not affect the percentage of innate
lymphoid cells (ILCs): ILC2, NCR or LTi ILC3s in the cLP, nor the number of
macrophages, although there was an increase in FCεRI+c-Kit+ mast cells in the cLP after
THC administration, which appeared to be mediated through CB2 (Figures 3.12E-J).
Moreover, THC 1X treated mice whose cLP was isolated and plated overnight showed
only small differences in cytokine production by an increase in IL-2 and IL-6 compared to
VEH treated mice (Figure 3.12K).
Cannabinoid receptor activation stems the progression of colitis-induced colon
cancer by reducing IL-22 production in the epithelial microenvironment.
Given the well-established propensity for colitis to lead to the development of colon
cancer (29,30), we next investigated the effect of THC or THC+CBD on a murine model
of colitis-associated colon cancer. To induce colon cancer, we used the well-established
model of carcinogen injection, azoxymethane (AOM, 10 mg/kg, ip), followed by three
cycles of DSS to induce colon carcinogenesis. We halted cannabinoid treatment after the
third DSS cycle to examine the effects of cannabinoids solely on cancer initiation, and not
the potential direct effects of cannabinoids on tumors. Disease progression and
experimental schematic is detailed in (Figure 3.13A), revealing that mice given
DSS+AOM to induce colon cancer (CC group) but treated with cannabinoids, lost less
weight compared to the CC + VEH group (Figure 3.13A). At termination of the study,
colonic tumors and spleen weights were increased in the CC + VEH group compared to
both CC + THC and CC + THC+CBD groups (Figure 3.13B-D). Colonoscopies revealed
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reduction in inflammatory severity as well as tumor induction in CC + THC and CC +
THC+CBD groups when compared to CC + VEH group (Figure 3.13E, F). Notable was
that consistent with earlier data shown in (Figures 3.1C, D; 3.2C, D; 3.7C) where we saw
that the colons of both disease and naive control mice given THC or THC+CBD had
increased colonic mucus, here we see mucus deposition persists after many weeks of
treatment (Figure 3.13E, F). Since CC + THC and CC + THC+CBD mice did not develop
any tumors, we looked at immune parameters relevant to carcinogenesis that might be
differentially regulated in the treatment groups. IL-22 is a cytokine produced by Th22 cells
and ILCs that is critical to the development, maintenance, and stemness of inflammationinduced colon cancer (105-107). The CC + VEH group had a significant increase in the
amount of CD4+IL-22+ Th22 cells in the intra-epithelial cell fraction (IEC) of the colon
compared to CC + THC and CC + THC+CBD groups, while there was no change in cLP
CD4+RORγt+ cells (Figure 3.13G-I). Taking the cells from the cLP and IEC and plating
them overnight to collect supernatants revealed that the increase in IL-22 seen in the
CC+VEH group in the colonic microenvironment is coming specifically from cells in the
IEC (Figure 3.13J, K), not the cLP.
3.5 DISCUSSION
The synergy between immune cells, enterocytes and symbiotic and pathogenic
microbes in the GI tract requires a delicately balanced network that can adapt as new
signals are acquired. A disruption in that balance can lead to chronic inflammation. Recent
epidemiological evidence suggests this disruption in the form of colitis is on the rise in
developing nations and its current burden in North America and Europe is daunting (2628). New strategies that can safely tip the gut equilibrium toward host defense without
sparking inflammatory cascades or leave the host vulnerable to other maladies will be the
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most effective strategy for preventing disease. In the current study, we demonstrated the
potential for cannabinoids in the prevention and amelioration of gut inflammation.
Previous reports have found that cannabinoids acting through CB1 can reduce gut motility
(49,85) and gastric acid secretion (86), and increase barrier integrity (49,51). Studies from
our lab and others have demonstrated the CB2 dependent anti-inflammatory properties of
cannabinoids working directly through immune cells (46, 48-50, 87). The work herein
builds on those studies to provide a comprehensive evaluation of how the most commonly
used cannabinoids, positively influence host gastrointestinal homeostasis through
increased coordination between immune cells, colonocytes and gut flora.
The most commonly consumed cannabinoids come in the form of recreational
marijuana, whose primary bioactive components are CBD and THC (41,42). With cannabis
legalization and public consumption of marijuana and CBD extracts increasing, it is
important to parse out the scientifically proven beneficial effects of these compounds to
cut through the noise of increasing anecdotal reports (41, 108, 112). Purified forms of CBD
come as the FDA-approved drug Epidiolex for epilepsy, and purified THC comes as
Dronabinol to treat spasticity and pain, among others (43, 108). A combination of THC
and CBD is sold under the trade name Sativex and is prescribed to treat the symptoms of
multiple sclerosis (42, 43). Numerous reports from animal studies and one prospective
placebo-controlled human study tout the effectiveness of cannabinoids for ameliorating
colitis (41, 42, 48-54). Our goal was to understand how each component, CBD and THC,
can affect disease course to best understand the therapeutic potential of these compounds.
To accomplish this, we used three models of colitis and one model of inflammation induced
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colorectal cancer, looking at gut immunity, barrier function and host-microbiota
interactions to gain a clear view of where the efficacy of cannabinoid in treating colitis lie.
In the TNBS and DSS model of colitis, THC and a combination of THC+CBD were
effective at preventing the symptoms of colitis, but CBD was not. Our results align with a
human trial on CBD for Crohn’s disease (55); however, their sample size was low, and it
is possible that in both cases the dose of CBD used was too low, as there are reports of
CBD being effective for treating inflammatory pain (108,109) and liver inflammation
(110,111). Nonetheless, THC was significantly more effective than CBD at protecting
against TNBS and DSS-induced colitis, with no significant benefit added when combining
CBD with THC. TNBS and DSS colitis are both induced via luminal delivery of
xenobiotics that induce colitis by damage to the epithelial layer and allowing microbes to
infiltrate host tissue in the case of DSS, and by disrupting the luminal mucus layer with
ethanol and haptenizing colonic proteins in the case of TNBS. In examining tissues from
THC and THC+CBD treated mice, we noticed less inflammation than the VEH and CBD
groups but also more mucus deposition into the luminal layer. We confirmed that THC
alone stimulates the production of Muc2 and Muc5ac after a single administration in naïve
mice, as well as in inflamed DSS-diseased mice. In addition to increasing mucus
production, THC also increases the expression of tight-junction proteins ZO-1 and Claudin.
Importantly, this effect was specific to the colon. This explains why, despite similarly
improved clinical parameters of disease, DSS mice treated with cannabinoids had gut
leakage comparable to VEH mice, while TNBS mice treated with cannabinoids did not.
DSS delivered in the drinking water will also break up the epithelial lining of the small
intestine and other parts of the GI tract, leading to leakage, while TNBS induced damage
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is specific to the colon. Using cannabinoid receptor (CB) knockout mice, MC38 and Caco2 adenocarcinoma cell lines, we were able to show that CB1 is responsible for the THCmediated increases in tight-junction proteins, confirming work by others (51). Novel to this
study was that the increase in mucus and β-defensins that occurs after THC administration
is dependent on both CB1 and CB2. The increase in mucus expression was prevalent in
mouse tissue, cell lines and human cell lines, but Caco-2 cells given THC had the opposite
trend in β-defensin production when administered THC, this could be attributable to the
nature of that cell line or a non-conserved mechanism. Regardless, additional human data
is needed to support this finding. The observed increases in colonic barrier integrity were
shown to be important for disease prevention, as mice pre-treated for 3 days with THC
developed less severe TNBS and DSS colitis compared to mice whose treatment began
concurrently with disease induction.
Importantly, the THC-mediated increase in tight-junction proteins and mucus were
seen only in the proximal colon samples, but not in the small intestine where there is less
contact with microbes. Mucus is a glycoprotein, that once deposited into the lumen
polymerizes into a polysaccharide gel. This gel is an excellent source of defense from
microbes and has been protective in colitis and colon cancer (95,96); however, it also acts
as fuel for microbes. The increase in mucus production and deposition after THC
administration may be why the changes in bacterial composition seen after THC
administration favor the gram-negative phyla of Bacteroidetes and Proteobacteria, two
phyla well known for their voracious appetite for carbohydrates (90). This would also
explain why those bacteria, which are commonly thought of as pathogenic with colitis (90,
91), were not disease promoting in our THC treated mice, because those bacteria were not
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opportunistic pathogens, simply a result of increase in their preferential food source.
Further support for this notion is the finding that acute administration of THC caused a
small increase in acetate and butyrate levels in the cecum, that is diminished after shortterm administration, indicating an initial burst of microbial mucus metabolism that wanes.
It would also explain why the fecal transfer from THC-treated mice was ineffective at
suppressing colitis progression. Yet another compensatory mechanism in this complex
interplay at the luminal surface is that the increased mucus production is balanced by an
increase in defensin production, as seen from both our in vivo animal experiments and in
vitro MC38 cells.
By increasing the mucus production from goblet cells, and the observed increases
in tight junction message expression, THC likely prevented the mechanism of action of
disease induction in TNBS and DSS colitis; consequently, we used the αCD40 model of
colitis to isolate the effects of THC on GI immunity. Injection of αCD40 causes acute
wasting disease and colitis dependent on secretion of inflammatory cytokines TNF-α, IL12 and IL-23 (97,98). We found THC reduced inflammation systemically and in the colon
in the αCD40 colitis model via reduction in gross intestinal pathology and circulating proinflammatory cytokines IFNγ and TNFα. Flow cytometry of the cLP and Treg-depleting
studies revealed in this inflammatory model, the most likely immune cell through which
THC exerts its most potent anti-inflammatory effects are DCs.
DCs are the master antigen-presenting cells, and a reduction in their ability to
stimulate other immune cells stops the overwhelming inflammatory cascade before it can
start. Acting through CB2, we demonstrated that THC can modulate DC phenotype
towards a more anti-inflammatory state, characterized by decreased expression of CD80 in
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vitro as well as in vivo in αCD40 colitic mice. DCs in the cLP can promote the expansion
of T regulatory cells. Several studies have examined this mechanism, suggesting that DCs,
primarily CD103+ DCs, upregulate CCR7 to migrate to the mLN where they secret TGFβ1 and retinoic acid to induce T regulatory cells (88). Our results showed that THC
administration in naïve mice and after αCD40 induced colitis caused a decrease in CCR7
expression on DCs in both the cLP and mLN, suggesting THC reduces DC migration
between gastrointestinal lymph tissue. In addition, we found that BMDCs treated with
THC and cells from the cLP of mice treated with THC exhibited increased levels of TGFβ1. Taken together these data indicate that THC causes DCs to, instead of migrating to the
mLN and induce Tregs, remain in the cLP, secrete TGF-β1, and increase the percentage of
Tregs and influence other local cell types through the anti-inflammatory actions of TGFβ1. Indeed TGF-β1 is critical for intestinal homeostasis. Global TGF-β1-/- mice develop
spontaneous colitis around 3-4 weeks of age, and DC specific knockout of TGF-β1 also
results in spontaneous colitis (102,103). Moreover, DCs are an important source and
activator of TGF-β1 in the intestine, necessary for controlling Treg and Th17
differentiation (103) and colonocyte homeostasis (104). The effect of THC on DCs is
consistent with the observation that THC treatment reduces APC activity in vitro in human
cells (44).
A frequently observed finding in studies examining the effect of cannabinoids on
the immune system is the ability of CB receptor activation to switch T helper phenotype
from Th1 to Th2 (47,48). We did not find evidence in our models for this switch to be
occurring. THC reduced Th1 activity, although there was no evidence through flow
cytometric analysis of CD4+Gata3 expression or in IL-4, IL-5 or IL-13 production that a
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Th2 phenotype was being induced. This suggested that in the gut, the effect of THC may
be different in that down-regulation of Th1 cells may not result from a switch from Th1 to
Th2 but mere suppression of Th1 cells by TGF-β, as shown in other studies (47,48,103).
Taken together these data indicate a sophisticated network of mechanisms through
which THC promotes cooperation and balance in the colonic macroenvironment. THCmediated decreases in DC activation reduce effector cell generation, while DC secretion of
TGF-β1 increases Tregs locally to promote tolerance. The decrease in immunogenicity
from cLP immune cells is counterbalanced by increased barrier integrity, mucus production
and antimicrobial peptide release that stave off unwanted microbial interference, while still
allowing for the uptake of their beneficial metabolites (Figure 3.14). We also showed,
crucially, these effects can last long term. In the AOM+DSS model of colorectal cancer,
THC and THC+CBD maintained a thick mucus layer and was able to reduce the amount
of intra-epithelial-infiltrating IL-22 producing Th22 cells. IL-22 has recently gained
attention for its carcinogenic properties in human patients as well as in animal models of
colon cancer by promoting cancer stemness through STAT-3 activation (99, 105-107). Our
results show THC decreased the amount of tumorigenic IL-22 in the colonocyte
microenvironment where cancer initiation and progression occur. Ultimately, the presented
data provide robust evidence for the multi-faceted efficacy of THC in colitis prevention.
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Table 3.1. Macroscopic scoring of colitis models.
Feature
Stool score

Description

Score

Normal, solid pellets
Loosely-shaped, moist pellets
Diarrhea
Occult blood presenta

0
1
2
35

Table 3.2. Mouse endoscopy and murine endoscopic index of colitis severity (MEICS).
Parameter

Translucency of the Colon Mucosa

Vascular Patter

Fibrin Visible

Stool Consistency
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Description

Score

Transparent

0

Moderate

1

Marked

2

Non-transparent

3

Normal

0

Moderate

1

Marked

2

Bleeding

3

None

0

Little

1

Marked

2

Extreme

3

Normal + solid

0

Still shaped

1

Unshaped

2

Spread

3

Table 3.3. List of Primers

Gene
Name
mMUC2
mMUC5ac
m18S
mβ-actin

Accession
Number
NM_023566
NM O88715
NR_003278
NM_007393

mβDefensin 1

NM_007843

mβDefensin 3

NM_013756

mZO-1

NM_009386

mClaudin1
8

NM_001194
921

mOccludin

NM_001360
536

mLyz-1
mLyz-2
hB2M

hRPLPO

hDEFB1

NM_013590
NM_017372

Primer

Sequence 5’  3’

Forward

CTACCATTACCACCACTAC

Reverse
Forward

GTCTCTCGATCACCACCATTT
CTGTAACACCCAGTGTCCTAAG

Reverse
Forward

AGGCTGGTAGAAGTAGGTAGAG
CGTCGTAGTTCCGACCATAAA

Reverse
Forward

TTTCAGCTTTGCAACCATACTC
GGCTGTATTCCCCTCCATCG

Reverse
Forward

CCAGTTGGTAACAATGCCATGT
CACAGGCTTCCTGGGATATAAA

Reverse
Forward

CGCTCTGGTTGGACAACTTA
TTGAGGAAAGGAGGCAGATG

Reverse
Forward

CGGGATCTTGGTCTTCTCTATTT
GCCGCTAAGAGCACAGCAA

Reverse
Forward

TCCCCACTCTGAAAATGAGGA
TGGGTTTTGTGGTGTCACTG

Reverse
Forward

GGTAGTTGAATACAGCGGTCAC
TTGAAAGTCCACCTCCTTACAGA

Reverse
Forward

CCGGATAAAAAGAGTACGCTGG
CCTCCAAGTAACAGGACTTCAG

Reverse
Forward

CTGACTGACAAGGGAGACTTTG
AGTTCTTCAGCCAGGAAGTG

Reverse
Forward

CCAAGATCAACTGGTCTCCTATAA
GAGGCTATCCAGCGTACTCCA

Reverse
Forward

CGGCAGGCATACTCATCTTTT
CCATTCTATCATCAACGGGTACAA

Reverse
Forward

TCAGCAAGTGGGAAGGTGTAATC
GGTGGGTCAAAATGTGTGAGT

Reverse

GCTGTGGTAGGTCAGGCTTC

NM_004048

NM_053275

NM_005218
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hDEFB103
A

NM_001081
551.3

Forward

TGCTCTTCCTGTTTTTGGTGC

Reverse

TGCCGATCTGTTCCTCCTTT

hZO-1

NM_001301
025

Forward

CGGTCCTCTGAGCCTGTAAG

Reverse
Forward

GGATCTACATGCGACGACAA
CACCTGTGCCCTGGAAGGC

Reverse

CGGTCACGTGGGGCAGGTTC

Forward

CGGGTCCACGAGGAGACGGT

Reverse

GCTTCTGCAGCCAGGCACGA

Forward

GAAGGTCGGAGTCAACGGATT

Reverse

CGCTCCTGGAAGATGGTGAT

hMUC2

NM_002457

hMUC5AC NM_017511

hGAPDH

NM_002046

76

Figure 3.1 Cannabinoids ameliorate TNBS-induced colitis and reduce effector cell
phenotypes. BALB/c mice were injected intrarectally with 100 mg/kg TNBS in 50%
ethanol. Starting three days before disease induction and continuing daily, mice were
gavaged with either: Vehicle (10% EtOH in PBS+Tween-80), CBD (10 mg/kg), THC
(10mg/kg) or a combination of THC and CBD (10 mg/kg, both), (n=10). Mice were
sacrificed at 5 days post disease induction and blood as well as organs of interest were
harvested and analyzed for colitis-relevant parameters. (A) Percent weight change and
(B) actual weight change over the course of disease. (C) Representative colonoscopy
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images taken on day 5. (D) Quantification of colitis scores at indicated timepoints
throughout disease course, (n=5 per group, per time point). (E) Representative image and
(F) length of colons at sacrifice (n=10). (G-I) ELISAs from serum at sacrifice
quantifying disease relevant biomarkers of colitis severity (n=4-5). (J) PAS stain of
proximal colons from representative mice taken at sacrifice. (K, M) Representative flow
cytometry psuedocolor dot plots (gate: Live,CD45+) displaying effector cell types from
the lamina propria of indicated mice at sacrifice. (O) Offset histograms of FoxP3
expression (gate: Live, CD45+CD4+) in colonic lamina propria at sacrifice. (L, N, P)
Quantification of flow cytometry results (n=6). Data are presented as mean ± SEM of
three independent experiments. *P<0.05, **P<0.01, ****P<0.0001 by Two-way
ANOVA with Tukey’s multiple-comparisons test.
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Figure 3.2 TNBS-induced colitis treated with cannabinoids supplemental data and
representative flow gating strategies BALB/c mice were injected intrarectally with 100
mg/kg TNBS in 50% ethanol. Starting three days before disease induction and continuing
daily, mice were gavaged with either: Vehicle (10% EtOH in PBS+Tween-80), CBD (10
mg/kg), THC (10mg/kg) or a combination of THC and CBD (10 mg/kg, both), (n=10).
(A) Representative colonoscopy images from mice at every time point assessed. (B-E)
Representative flow cytometry gating strategies.
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Figure 3.3. Cannabinoids prevent DSS-induced colitis and reduce effector cell
phenotypes. To induce DSS-colitis, C57BL/6 mice were treated with either: Vehicle
(10% EtOH in PBS+Tween-80), CBD (10 mg/kg), THC (10mg/kg) or a combination of
THC and CBD (10 mg/kg, both) for 3 days before 2% DSS was added to their drinking
water. DSS remained in the drinking water until termination of the study 14 days later.
Mice were sacrificed at 14 days post disease induction and blood as well as organs of
interest were harvested and analyzed for colitis-relevant parameters. (A) Percent weight
change and (B) stool score assessed over the course of disease (n=5). (C) Representative
colonoscopy images taken on day 10. (D) Quantification of colitis scores at indicated
timepoints throughout disease course (n=8 per group, per time point). E Representative
image and (F) length of colons at sacrifice (n=5). (G-I) ELISAs from serum at sacrifice
quantifying disease relevant biomarkers of colitis severity (n=10, SAA; n=5, LCN-2,
80

MPO). J PAS stain of proximal colons from representative mice taken at sacrifice. (K,
M, O) Representative flow cytometry psuedocolor dot plots (gate: Live,CD45+)
displaying effector cell types from the lamina propria of indicated mice at sacrifice. (L,
N, P) Quantification of flow cytometry results (n=4-8). Data are presented as mean ±
SEM of three independent experiments. *P<0.05, **P<0.01, ****P<0.0001 by Two-way
ANOVA with Tukey’s multiple comparisons test.
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Figure 3.4 DSS-induced colitis treated with cannabinoids supplemental data To induce
DSS-colitis, C57BL/6 mice were treated with either: Vehicle (10% EtOH in
PBS+Tween-80), CBD (10 mg/kg), THC (10mg/kg) or a combination of THC and CBD
(10 mg/kg, both) for 3 days before 2% DSS was added to their drinking water. DSS
remained in the drinking water until termination of the study 14 days later. Mice were
sacrificed at 14 days post disease induction and blood as well as organs of interest were
harvested and analyzed for colitis-relevant parameters. (A) Representative colonoscopy
images from mice at every time point assessed. (B) Actual weight change throughout the
experiment (n=5). (C) Representative overlaid histograms displaying FoxP3 expression
in the cLP at sacrifice (gate: Live, CD45+CD4+). (D) Quantification of flow cytometry
results (n=8). Data are presented as mean ± SEM of three independent experiments.
*P<0.05, **P<0.01, ****P<0.0001 by Two-way ANOVA with Tukey’s multiple
comparisons test.
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Figure 3.5. Cannabinoid receptor 1 activation leads to increases in gram-negative
bacteria and short-chain fatty acid dysregulation that are inconsequential to DSS
progression Stool was collected before any compound administrations (Pre-Tx n=15),
and after five administrations of VEH (n=12) or THC (n=11), DNA was extracted and
subjected to 16S rRNA sequencing. (A) Stacked bar plot displaying % OTUs of phyla of
indicated groups. (B) % OTUs of the phylum Bacteroidetes and (C) Proteobacteria. (D)
% OTUs of the classes of Proteobacteria. WT mice were given a single (n=10) (E) or five
(n=9) (F) administrations of VEH or THC, sacrificed one day later and cecal contents
were analyzed for SCFAs. (G) LDA score of Cnr2-/- mice before (n=6) or after five
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administrations of VEH or THC (n=3). (H) SCFA analysis of Cnr2-/- mice (n=4), given
five VEH or THC administrations. (I) PCOA plot displaying the bacterial community
clustering from indicated mice on day 14 of DSS colitis (n=5). (J) Cecal SCFA
quantification of indicated mice (n=5). Letters above error bars indicate p<0.05 against
the indicated group, a=DSS+VEH, b=DSS+CBD, c=DSS+THC, d=THC+CBD. Mice
were given antibiotics (ABX) in their drinking water for 4 weeks before antibiotic-free
water was returned, mice were placed in the cages of donor fecal transfer (FT) mice
containing their used bedding. Three days after cessation of antibiotics, mice were given
daily fecal transfers from stool of indicated donor mice. DSS (2%) was administered in
the drinking water after three days of fecal transfers and (K) body weight was recorded
throughout the study (n=7-8 per group). Data are presented as mean ± SEM. Fecal
transfer experiment was repeated three times. *P<0.05, **P<0.01, ****P<0.0001 by
Two-way ANOVA with Tukey’s multiple comparisons test.
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Figure 3.6. Cannabinoid receptors mediate the gut flora and short-chain fatty acid
changes seen after THC administration (A, B, C, F) Mice of indicated genotype were
given one (1X) or five (5X) administrations of VEH or THC and sacrificed 24 hours later.
Their cecal contents were removed and SCFAs were quantified by GC-MS (n=5, all
groups). (D, E) LDA score of significant bacterial changes occurring between groups.
(G) qRT-PCR results from PC or SI of WT, Cnr1-/- or Cnr2-/- mice taken 24 hours after
one administration of VEH or THC. Data are presented as mean ± SEM of two
independent experiments. *P<0.05, **P<0.01, ****P<0.0001 by Two-way ANOVA with
Tukey’s multiple comparisons test or by Students t-test.
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Figure 3.7. Cannabinoids utilize both cannabinoid receptors to specifically increase
colonic barrier integrity and mucus production to protect against colitis induction (A)
and (B) At day 4 of the TNBS-colitis (n=5-10) and day 13 of the DSS-colitis experiment
(n=5), mice were fasted overnight and the next morning were gavaged with 100 uL of
4kD FITC-Dextran (600 mg/kg), 4 hours later blood was collected by retroorbital bleed,
and serum was analyzed for the presence of FITC-Dextran as a measure of gut
permeability. (C) PAS stain of proximal colon from mice after one or five VEH or THC
86

administrations. (D) qRT-PCR results from proximal colon (PC) or small intestine (SI)
24 hours after one administration of VEH or THC (n=5-7). (E) qRT-PCR results from PC
of mice who received DSS (2%) in their drinking water for 13 days. (F) MC38 cells were
treated with VEH, CBD, THC, or a combination of THC and CBD (all 10μM), for six
hours before RNA was collected and qRT-PCR was run on indicated genes (n=4). (G)
Caco-2 cells were treated with VEH, THC, AM251 (AM) or SR144528 (SR), or a
combination where indicated for 12 hours before RNA was collected and qRT-PCR was
run on indicated genes (n=6). TNBS and DSS colitis models were induced as was done
previously but we used three groups. The VEH and THC Pre-Tx (THC, 10mg/kg, oral
gavage) group received treatments beginning three days before colitis initiation, while the
THC Tx group began receiving daily treatments the same day colitis was induced. (H, J)
Percent weight change over the disease course, and (I, K) colon lengths at sacrifice
(n=5). Data are presented as mean ± SEM. *P<0.05, **P<0.01, ****P<0.0001 by Twoway ANOVA with Tukey’s multiple comparisons test.

87

Figure 3.8. THC treatment reduces αCD40 colitis severity through a reduction in
dendritic cell activity Mice were pre-treated daily with VEH or THC (10 mg/kg) for 3
days before intraperitoneal injection of rat anti-mouse IgG (control) or rat anti-mouse
αCD40 (200 μg, clone FGK4.5 in PBS) and treatment continued for 7 days post disease
induction to monitor progression of inflammatory severity. (A) Percent weight change
over the course of disease (n=3-10). Spleen weight (n=3-10) (B) and absolute mesenteric
lymph node cell number (n=3-6) (C) were recorded at sacrifice. At peak of disease on
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day 3, blood was collected via retroorbital bleed, serum was separated and subjected to
Legendplex assay for serum T helper cytokine levels (D) (n=3 per group). (E)
Representative images of colonoscopies performed at peak of disease on day 3, and their
quantification in (F) (n=4 per group). (G) Representative overlaid histograms displaying
CD45+ cell percentages from the colonic lamina propria of indicated mice at sacrifice.
(H) Quantification of CD45 percentages and (I) absolute cell counts of CD45+ colonic
lamina propria cells. (J) Representative contour plots of macrophages (gate: Live,
CD45+) (n=3-5) and (L) dendritic cells (gate: Live, CD45+) (n=5-8). (N) Representative
contour plots of cLP dendritic cell subsets at sacrifice (gate:
Live,CD45+MHCIIHICD11c+) (n=3-9). (K, M, & O) Quantification of flow cytometry
results. Data are presented as mean ± SEM. *P<0.05, **P<0.01, ****P<0.0001 by Twoway ANOVA with Tukey’s multiple comparisons test.

89

Figure 3.9. THC treatment reduces dendritic cell activation lessening the severity of
αCD40 colitis Mice were pre-treated for 3 days with VEH or THC before disease
induction via i.p. injection of 200 μg anti-mouse αCD40 or IgG control. Treatments
continued until sacrifice seven days post disease induction. At sacrifice, mLNs or cLPs
were taken and analyzed by flow cytometry for immune cells of interest. (A, C)
Representative overlaid histograms displaying CD80 and CD86 expression in cLP
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macrophages, (A) (gate: Live, CD45+CD11b+F4/80+), and in cLP dendritic cells (C)
(gate: Live, CD45+MHCIIHICD11c+). (E, G, I, K) Representative flow cytometry plots
from the mLN of CD8+IFNγ+ cells (E) (gate: CD3+CD4-CD8+); IL-17A and IFNγ
single and double positive cells (G) (gate: CD3+CD4+); IL-10 and IL-4 positive cells (I)
(gate: CD3+CD4+); and dendritic cell subsets (K) (gate: MHCIIHICD11c+). (F, H, J, L)
Quantification of flow cytometry results (n=3 IgG groups, n=5-7 αCD40 groups). Data
are presented as mean ± SEM of two independent experiments. *P<0.05, **P<0.01,
****P<0.0001 by Two-way ANOVA with Tukey’s multiple comparisons test.
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Figure 3.10. Dendritic cell re-programming and not Treg induction are the mechanism
through which THC ameliorates αCD40-induced inflammation. Mice were pre-treated
for 3 days with VEH or THC before disease induction via i.p. injection of 200 μg antimouse αCD40 or IgG control. Treatments continued until sacrifice seven days post
disease induction. (A) Representative flow cytometry contour plots of n- and iTregs in
the cLP (gate: Live,CD45+CD4+). (B) Quantification of flow cytometry results (n=3-8).
Mice were pre-treated with VEH or THC for 2 days before depletion of Tregs via i.p.
injection of rat anti-mouse CD25 (clone PC61, 100 mg/kg) or isotype control. The next
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day disease was induced by i.p. injection of αCD40 or IgG control. (C) Weight was
monitored, and spleen weight was recorded on day 7 at sacrifice (D) n=3 IgG, n=5
αCD40 + IgG, n=7 αCD40 + αCD25). Data are presented as mean ± SEM. *P<0.05,
**P<0.01, ****P<0.0001 by Two-way ANOVA with Tukey’s multiple comparisons test.
Naïve mice were administered VEH or THC once and 24 hours later were sacrificed and
cLP and mLN were harvested. Representative contour plots of dendritic cell subsets in
the cLP (E) and mLN (H), that are quantified in (F) and (I), respectively (n=5 per group).
1x106 live cLP or mLN cells from indicated groups were plated in complete media
overnight, spun down, and supernatants were collected and subjected to sandwich ELISA
for TGF-β1 quantification. TGF-β1 levels in the cLP (G) (n=5) and mLN (J) (n=3)
supernatants of indicated groups. (K) Overlaid histograms of CCR7 expression in DCs
from indicated mice in the cLP or mLN. (L) Mean fluorescence intensity of CCR7
expression (n=5). TGF- β1 levels from the supernatant of BMDCs treated with VEH or
THC after 7 days of culture (M) or after one day of culture after CD11c+ cell selection
(N) (n=3 per group). Data are presented as mean ± SEM. *P<0.05, **P<0.01,
****P<0.0001 by Students t-test.
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Figure 3.11. THC reduces pro-inflammatory DCs and decreases CD80 expression to
reduce T cell responses. BALB/c mice were injected intrarectally with 100 mg/kg TNBS
in 50% ethanol. Starting three days before disease induction and continuing daily, mice
were gavaged with either: Vehicle (10% EtOH in PBS+Tween-80), CBD (10 mg/kg),
THC (10mg/kg) or a combination of THC and CBD (10 mg/kg, both). (A) Representative
contour plots of cLP dendritic cell subsets at sacrifice (gate:
Live,CD45+,MHCIIHICD11c+) (n=7). C57BL/6 mice were treated with either: Vehicle,
CBD (10 mg/kg), THC (10mg/kg) or a combination of THC and CBD (10 mg/kg, both)
for 3 days before 2% DSS was added to their drinking water. DSS remained in the
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drinking water until termination of the study 14 days later. Mice were sacrificed at 14
days post disease induction and cLP was isolated and stained for markers of dendritic cell
phenotype CD103 and CD11b. (C) Representative contour plots of cLP dendritic cell
subsets at sacrifice (gate: Live,CD45+,MHCIIHICD11c+) (n=7-8). Bone marrow cells
were cultured in vitro with GM-CSF, IL-4 and either THC (10µM) or VEH for 7 days to
induce dendritic cell generation from bone marrow precursors. (E) Representative
overlaid histograms of CD80 and CD86 expression gated on dendritic cells
(MHCIIHICD11c+). (B, D, F) Quantification of flow cytometry results. After 6 days of
BMDC generation, CD11c+ cells were selected from wells treated with either THC or
VEH and then co-cultured with naïve CFSE-pulsed CD3+ T cells at a ratio of 1:5, DCs :
T cells. Un-stimulated wells received 50µg of IgG control antibody, while experimental
groups received 50µg of anti-CD40. Cells were collected daily for flow cytometric
analysis of CFSE dilution among CD4 and CD8 T cell subsets after being co-cultured
with VEH or THC treated DCs. (G) Representative offset histograms of CFSE expression
gated on CD4 cells (upper panel) or CD8 (lower panel) after incubation with VEH or
THC treated DCs and stimulated with IgG (control – unstimulated), or anti-CD40. Data
are presented as mean ± SEM. *P<0.05, **P<0.01, ****P<0.0001 Two-way ANOVA
with Tukey’s multiple comparisons test (A-D) or by Students t-test (E, F).
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Figure 3.12. THC administration causes cLP immune cell phenotype changes through
CB2. Mice were given one administration of VEH or THC and were sacrificed 24 hours
later. cLP was harvested and analyzed via flow cytometry for immune cell populations of
interest. (A) Contour plots displaying FoxP3+Helios+ nTregs and FoxP3+Helios- iTregs
(gate: Live, CD45+CD4+). (C) Contour plots displaying total cLP DCs (right column)
and DC phenotype (left column, gate: Live,CD45+MHCIIHICD11c+) from indicated
mice. (B, D) Quantification of flow cytometry results (n=3-5 per group). (E, F)

96

Representative pseudocolor dot plots displaying CD11b+F4/80+ macrophages (E) (gate:
Live, CD45+), and FCεRI+C-kit+ mast cells (F) (gate: Live, CD45+CD11b+) in the cLP.
(G, H) Quantification of flow cytometry results (n=4 per group). (I, J) Histogram and dot
plots showing NCR ILC3s (Lineage-CCR6+NKp46+), LTi ILC3s (LineageCCR6+NKp46-) and ILC2s (Lineage-Gata3+). (K) 1x106 live cLP cells from the
indicated groups were plated overnight, supernatants were collected, and subjected to
Legendplex assay for Mouse T helper cytokines (n=2 per group). Data are presented as
mean ± SEM. *P<0.05, **P<0.01, ****P<0.0001 by Students t-test.

97

Figure 3.13. Cannabinoid receptor activation stems the progression of colitis-induced
colon cancer by reducing IL-22 production in the epithelial microenvironment. To
induce colitis-associated colon cancer (CC), mice were given a single injection of AOM,
i.p. (10 mg/kg), then 1 week later treatment started concurrently with the induction of the
first cycle of colitis with 2% DSS in the drinking water. Weeklong cycles of DSS (2%)
were followed by 2 weeks of regular drinking water for 3 cycles lasting 9 weeks.
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Treatment with VEH (10% EtOH in PBS-Tween-80), THC (10 mg/kg) or a combination
of THC and CBD (10 mg/kg, both) were given twice a week until the last DSS cycle was
completed and then treatments were halted to monitor the effects of cannabinoids on
induction of cancer, not the direct effects of the cannabinoids on cancer itself. Control
mice were treated twice weekly, but disease was not induced (ctrl). (A) Diagram showing
percent weight change, treatment schedule and disease course. (n=5, ctrl groups; n=7-9
CC groups). (B) Graph showing the number of tumors in each colon at sacrifice. (C)
Representative photo and (D) quantification of spleen weights from indicated mice at
sacrifice. Colonoscopies were performed throughout the experiment and representative
images are shown in (E) and quantified in (F) (n=5-8, ctrl groups; n=8 CC groups). cLP
and intra-epithelial cell fraction (IEC) was isolated at sacrifice and stained for
CD4+RORγt+ and CD4+IL-22+ Th22 cells. (G) Representative contour plots displaying
CD4+RORγt+ Th17 cells in the cLP (top two panels) and CD4+IL-22+ Th22 cells in the
IEC fraction (bottom two panels). (H, I) Quantification of flow cytometry plots (n=3, ctrl
groups; n=6, CC groups). (J, K) 1x106 cells deriving from the cLP or IEC layers from
indicated groups were plated overnight, supernatants were collected and subjected to
ELISAs for TGF-β1 (n=3, ctrl groups; n=6, CC groups). Data are presented as mean ±
SEM. *P<0.05, **P<0.01, ****P<0.0001 by Two-way ANOVA with Tukey’s multiple
comparisons test. AOM-DSS model was repeated twice. Data presented are from 1
experiment.

99

Figure 3.14. Graphical abstract of THC-induced effects in the colonic
microenvironment
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CHAPTER 4: SUMMARY & CONCLUSIONS

Inflammation is at the heart of a growing number of diseases. Strategies to govern
our immune system so that immunogenecity towards symbiotic commensals or the gift of
a crucial yet foreign organ transplant are needed. The work presented display how research
examining the nature and treatment of disease can reveal innovative strategies for
regulating inflammation.
In a model of allogeneic organ transplantation, we examined how a cluster of
miRNAs induced after exposure to alloantigen in graft-responding CD4+ T cells work to
reduce the activity of anti-inflammatory TGF-β2. We showed that TGF-β2 has the same
potency in inducing Tregs as TGF-β1, and that increasing TGF-β2 levels in vivo by
blocking the interfering miRNA cluster can reduce inflammatory severity. Advances in
treating graft rejection may use TGF-β2 to induce Tregs, and we established a new miRNA
cluster as a target for alleviating inflammation.
Cannanoids are natural compounds extracted from the Cannabis sativa plant.
Evidence for their therapeutic efficacy in treating several diseases is growing. The rate of
colitis and colon cancer globally are rising, thus new strategies to prevent them are critical.
We tested the most frequently consumed cannabinoids, CBD and THC, alone and in
tandem to illuminate which component has the greatest therapeutic efficacy in preventing
colitis and colitis-associated colon cancer. Our results revealed that THC was very effective
at preventing the inflammation induced by three separate models of colitis with disparate
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etiologies and one model of colitis-associated colon cancer. We found that CBD had no
colitis-preventative value at the dose tested, and if it synergized with THC for a greater
effect, the effect was minimal and relegated to longer term models.
THC prevented colitis in two models by increasing the defenses around the colonic
microenvironment. THC acted directly on colonocytes and goblet cells to stimulate tightjunction protein and mucus production that are the first line of defense against luminal
disturbances and microbes. The increased mucus became a source of food for commensal
microbes that led to an increase in the SCFAs acetate and butyrate being secreted after
acute THC administration. The changes in bacterial composition seen after THC
administration were increases in gram negative Bacteroidetes and Proteobacteria. While
these bacteria were not pathogenic in THC treated mice, they also were not the mechanism
through which THC protects against colitis development, as fecal transfers from THC
treated mice did not alleviate colitis. THC, working through CB1 and CB2, stimulates the
secretion of anti-microbial peptides from colonocytes to balance the increase in gramnegative bacteria. Mice treated prophylactically with THC built up a thicker mucus layer
and displayed more protection from colitis than mice who received treatment to alleviate
disease.
We utilized a model of colitis that acts solely on the immune system to examine the
gut immunological benefits of THC on colitis development. Our work revealed that THC,
through CB2, acts directly on dendritic cells (DCs) to stimulate TGF-β1 production that
can induce Tregs and directly suppress effector T cells in the colonic lamina propria. THC
also reduces DC migration between gut lymphatic tissue, reducing the expansion of T cells
induced in anti-CD40, TNBS and DSS models of colitis. In the AOM + DSS model of
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colitis-associated colon cancer, THC proved efficacious at preventing colitis and
associated cancer in a longer model, displaying prolonged mucus secretion and a reduction
in intra-epithelial IL-22 secreting Th22 cells, which can promote cancer. Our data paint a
picture wherein THC enacts a sophisticated network of interaction between colonocyte
production of mucus and defensins to regulate the gut microbiota, while calming the
underlying immune cells from ruinous inflammation through DC secretion of TGF-β1 and
the induction of Tregs.
Through an examination of the mechanisms that cause and prevent inflammation,
the work described in this dissertation reveal epigenetic, molecular and cellular pathways
that regulate inflammation.
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